Mitochondrial complex 1 modulators for use in the treatment or prevention of muscle loss
MCIM compounds address the lack of therapies for muscle loss by modulating mitochondrial Complex I to stimulate satellite cell activity, enhancing muscle regeneration and strength in conditions like sarcopenia and cachexia.
Patent Information
- Application Number
- PCT/EP2026/063506
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2026-03-06
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
There are no effective therapies for muscle loss conditions such as sarcopenia and cachexia, which are prevalent in various diseases and aging, leading to debilitating muscle atrophy and functional limitations.
MCIM compounds, which modulate mitochondrial Complex I, are administered to inhibit muscle loss and promote muscle regeneration by stimulating satellite cell expansion and differentiation, thereby increasing muscle mass and reducing atrophy.
MCIM compounds effectively prevent further muscle loss, promote muscle regeneration, and improve muscle function by increasing muscle mass and strength, as evidenced by histological and functional improvements in animal models and human patients.
Smart Images

Figure EP2026063506_12112026_PF_FP_ABST
Abstract
Description
[0001] MITOCHONDRIAL COMPLEX 1 MODULATORS FOR USE IN THE TREATMENT OR PREVENTION OF MUSCLE LOSS
[0002] Field of the Invention
[0003] The present invention relates to a class of therapeutic agents that can inhibit and / or reverse muscle loss in a variety of contexts, including muscle loss associated with a range of progressive and / or degenerative diseases. The therapeutic agents of the invention can act by binding mitochondrial Complex I.
[0004] Collectively, the therapeutic agents of the invention are referred to herein as Mitochondrial Complex I Modulator compounds (or MCIM compounds).
[0005] Background
[0006] Skeletal muscle plays an essential role in controlling voluntary movements, maintaining posture, respiration and metabolic function. Accordingly, muscle loss, or muscular atrophy, is regularly debilitating and can have a significant impact on quality of life. In simple terms, muscle loss occurs when the rate of muscle protein degradation exceeds protein synthesis and / or muscle cell loss exceeds myogenesis. In healthy individuals, these processes coexist in equilibrium, which is maintained thanks to the ability of muscle to regenerate and recover normal architecture and contractile function following both everyday stress and acute damage. Moreover, this regeneration process allows muscle tissue to adapt and match the repeated physiological demands of daily life (such as physical exercise).
[0007] Muscle regeneration is dependent on the proliferation and differentiation of muscle stem cells known as satellite cells or myosatellites. Under normal physiological conditions, satellite cells exist in a microenvironment niche in a quiescent state where they proliferate sporadically to replace muscle myofibres damaged by daily activity. However, following major muscle tissue damage or atrophy, quiescent satellite cells are activated by signals from the satellite cells niche, triggering satellite cell proliferation and subsequent differentiation into myoblast and myocytes, which fuse at the site of damage leading to muscle fibre regeneration and muscle repair. A proportion of activated satellite cells do not commit to differentiation but instead continue to self-renew and replenish the quiescent satellite cell pool within the satellite cell niche.
[0008] Muscular loss occurs when muscle regeneration cannot match the rate of muscle damage and / or muscle fibre atrophy. The progressive loss of muscle mass and strength with a risk of adverse outcomes such as disability, poor quality of life and death is known as sarcopenia (Ali and Garcia, 2014). The term sarcopenia is typically associated with loss of muscle mass and strength associated either with ageing, or with a cause such as a medical condition. Indeed, multiple medical conditions are associated with sarcopenia, including, for example, cancer, HIV / AIDS, obesity, metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), idiopathic pulmonary fibrosis (IPF), Alzheimer’s disease, chronic obstructive pulmonary disease (COPD) and rheumatoid arthritis. As such, the term ‘primary sarcopenia’ is now given to age-related sarcopenia without any known cause, while sarcopenia that results from one or more causes is termed ‘secondary
[0009] 008754913 May 2025sarcopenia’ (Moschou et al., 2023). In the former, sarcopenia may be associated with other musculoskeletal changes, such as osteoporosis (osteosarcopenia) or obesity (sarcopenic obesity), or, indeed, with both obesity and osteoporosis (osteosarcopenic obesity), or be seen alongside metabolic changes such as steatohepatosis. Secondary sarcopenia may be associated with many conditions. For example, Rheumatoid arthritis (RA) or inflammatory bowel disease (IBD) can result in secondary sarcopenia, which can be driven by a lack of movement, reduced nutritional uptake or ongoing inflammation. Indeed, in sarcopenia, chronic low-grade inflammation including changes in IGF1, CRP, TNFα and IL6 contributes to changes in anabolism, as well as altering the function of satellite cells (Dalle et al., 2017). As well as its association with ageing and with disease, sarcopenia can be induced or exacerbated by therapeutics administered to treat certain disorders, such as glucocorticoids for autoimmune, autoinflammatory lymphoproliferative or neuromuscular diseases (Lee et al., 2022), or antidiabetic drugs (Zhang, 2021).
[0010] Muscle loss is also seen in cachexia, a multi-factorial syndrome in which muscle loss is accompanied by severe body weight and fat loss due to an underlying illness. For example, cachexia is observed in 10-40% of patients with chronic conditions such as heart failure, renal failure, liver failure or cancer. In cancer alone it is estimated that 20% of patients with solid cancers die directly as a result of cachexia (Argiles et al 2014)). Cachexia remains poorly recognized, treated and prevented. Inflammation within muscle tissue is thought to indirectly and directly drive the progression of muscle atrophy and is known to suppress protein synthesis and stimulate proteolysis in cachexia. This is associated with elevated levels of pro-inflammatory cytokines and enhanced activation of the pro-inflammatory signalling pathways IGF-1 / Akt and NF-κB pathways (Ji et al., Antioxidants 2020 11(9), 1686). Like sarcopenia, cachexia can be exacerbated by therapeutics used to treat certain disorders, such as by chemotherapeutics for cancer (Campelj et al., 2021).
[0011] Despite the many disease settings or ageing phenotypes in which sarcopenia or cachexia may be observed, common pathological features of muscle loss are observed. These include muscle fibre atrophy, decreased protein synthesis and mitochondrial alterations, alongside functional limitations and inflammation (Dalle et al., 2027). Nevertheless, and despite the burden sarcopenia poses, there are no approved therapies for either sarcopenia or cachexia.
[0012] In autoimmune disease such as RA and IBD, fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and neurological diseases such as multiple sclerosis (MS) and Alzheimer’s disease, there is a predisposition to sarcopenia. Sarcopenia occurs in approximately 66% of patients with RA (Moschou et al., 2023). Various factors are thought to contribute to this, including the presence of inflammatory cytokines such as TNFα and IL6, elevated CRP, and increased BMI, fat mass and osteoporosis. The combination of low IGF1 hormone and high IL6 confers a high risk of progressive disability and sarcopenia in RA patients. Current treatment options for RA and IBD include conventional diseasemodifying antirheumatic drugs (DMARDs; e.g methotrexate, azathioprine, chloroquine, D-penicillamine ciclosporin, gold salts such as sodium aurothiomalate and auranofin), glucocorticoids, and
[0013] 008930943immunosuppressants which target TNFα, CTLA-4, IL6, CD20, IL1, JAK / Tyk, PDE4, IL23 and IL17 signalling pathways.
[0014] Whilst these agents are effective in suppressing symptoms and improving quality of life, a high proportion of patients nevertheless report ongoing disability (Ochi et al. 2024) potentially as a consequence of sarcopenia as a comorbidity (Dhaliwal et al., 2021). Despite the high prevalence of sarcopenia in RA and IBD, the best management options remain exercise and diet (Bennett et al., 2023, Galvez et al., 2024). However, whilst in exercise therapy moderate activity may be effective in improving muscle mass and strength, intensive exercise may exacerbate the inflammatory response (Torii et al., 2023). Furthermore, several reports suggest that glucocorticoids, which are commonly prescribed for RA and IBD may exacerbate muscle loss (Fenton et al., 2019, Bodine et al., 2015), and there is no conclusive data showing a beneficial effect of DMARD therapy (including conventional synthetic, biological and targeted synthetic DMARDs) on skeletal muscle mass in RA. Indeed, patients with RA who are able to achieve low disease activity or remission based on their symptoms nevertheless present with impaired physical function, low muscle function and strength, and both sarcopenia and / or myopenia with approximately 60% of patients in low disease activity exhibiting low muscle function (Jia et al., 2025).
[0015] Accordingly, there is an unmet need for an effective treatment for muscle loss. Such a therapy would find use in both autoimmune diseases such as RA and IBD, but also in the treatment of muscle loss more generally, both in primary and secondary sarcopenias given the conserved pathology. Such an agent may also find use in conditions such as osteosarcopenia, sarcopenic obesity or osteosarcopenic obesity. The present invention has been devised in light of the above considerations.
[0016] Summary of the Invention
[0017] The present invention relates to a novel use of MCIM compounds in the treatment or prevention of muscle loss. The inventors have found, for the first time, that administering MCIM compounds to subjects experiencing muscle loss can prevent further loss of muscle mass and promote regeneration and repair of muscle tissue.
[0018] In view of the above, at its broadest, the present invention provides an MCIM compound for use in the treatment of muscle loss in a subject. Preferably, the compounds bind Complex I and are able to modulate Complex I function
[0019] Accordingly, in a first aspect, the present disclosure provides a mitochondrial complex 1 modulator (MCIM) compound for use in the treatment or prevention of muscle loss in a subject, wherein the treatment comprises administering to the subject a compound, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, according to a formula selected from:
[0020]
[0021] defined in claim 1 of WO2010 / 032009;
[0022] 008930943
[0023]
[0024] In some embodiments, the muscle loss is sarcopenia, optionally primary sarcopenia or secondary sarcopenia. In some embodiments, the muscle loss is cachexia, optionally cachexia associated with disease, or drug-induced cachexia. In some embodiments, the muscle loss muscular atrophy associated with inactivity. In some embodiments, the muscle loss is associated with a neuromuscular disorder. In some embodiments, the muscle loss can be any combination of the aforementioned types of muscle loss. In some embodiments, the secondary sarcopenia is induced by, exacerbated by, or associated with an autoimmune disease, a fibrotic disease and / or a neurological disease. In some embodiments, the autoimmune disorder is rheumatoid arthritis or inflammatory bowel disease (IBD). In some embodiments, the secondary sarcopenia is osteosarcopenia. In some embodiments, the secondary sarcopenia is sarcopenic obesity.
[0025] In some embodiments, the secondary sarcopenia is induced by, exacerbated by and / or associated with a treatment, treatment strategy, therapeutic, medicine and / or drug. In some embodiments, the treatment, treatment strategy, therapeutic, medicine and / or drug is for the treatment of diabetes, cancer, an autoinflammatory condition, an autoimmune condition, metabolic dysfunction-associated steatohepatitis (MASH) or metabolic dysfunction-associated steatotic liver disease (MASLD), and / or a neuromuscular condition. In some embodiments, the drug is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or a steroid.
[0026] In some embodiments, the neuromuscular disorder is muscular dystrophy or ALS.
[0027] In some embodiments, the cachexia and / or sarcopenia is associated with cancer, pancreatic cancer, stomach cancer, oesophageal cancer, colorectal cancer, chronic obstructive pulmonary disease (COPD), heart failure, chronic kidney disease, HIV / AIDS, sepsis, Emphysema, organ failure, Alzheimer’s disease, dementia, congestive heart failure (CHF), chronic kidney disease cystic fibrosis, arthritis, rheumatoid arthritis, Crohn's disease, tuberculosis, colitis, MASH, MALSD, IPF, or any disease with associated muscle loss.
[0028] 008930943In some embodiments, the subject to be treated is identified as having a HAQ-DI score of 1-3; a SARC-F score of 4 or more; a CASCO classification of mild, moderate, severe or terminal; a visual reduction in muscle mass and / or symmetry indicative of muscle wasting and / or atrophy; and / or a BMI over 30.
[0029] In some embodiments, administration of the compound to the subject reduces the HAQ-DI score, the SARC-F score, the CASCO score, or visual signs of muscle loss in a subject. In some embodiments, administration of the compound to the subject improves visual signs of muscle mass and / or muscle symmetry. In some embodiments, administering the MCIM compound reduces the HAQ-DI score of a subject.
[0030] In some embodiments, administration of the compound to the subject increases muscle mass of the subject compared to the muscle mass of the subject prior to commencing treatment with the compound. In some embodiments, administration of the compound to the subject maintains muscle mass of the subject compared to the muscle mass of the subject prior to commencing treatment with the compound, In some embodiments, the subject has a muscle wasting disease or disorder. In some embodiments, administration of the compound to the subject reduces the rate of loss of muscle mass in a subject compared to the rate of loss of muscle mass in the subject prior to commencing treatment with the compound. In some embodiments, administration of the compound to the subject results in any combination of increasing muscle mass, maintaining muscle mass, and / or reducing the rate of muscle loss as described above.
[0031] In some embodiments, administration of the compound to the subject increases muscle hypertrophy and / or the cross-sectional area of muscle fibres of the subject compared to the subject prior to commencing treatment with the compound; and / or maintains muscle hypertrophy and / or the cross-sectional area of muscle fibres of the subject compared to the subject prior to commencing treatment with the compound.
[0032] In some embodiments, administration of the compound to the subject reduces muscle fibre atrophy, myositis, fibre degeneration, oedema, fat inclusion size and / or fat inclusion number in the muscle tissue, or any combination thereof, compared to the subject prior to commencing treatment with the compound and / or inhibits muscle fibre atrophy, myositis, fibre degeneration, oedema, development of fat inclusions in the muscle tissue, or any combination thereof, compared to the subject prior to commencing treatment with the compound.
[0033] In some embodiments, muscle mass, muscle hypertrophy, muscle fibre atrophy, myositis, fibre degeneration, oedema, fat inclusion size and / or fat inclusion number is measured using ultrasonography, magnetic resonance imaging (MRI), computed tomograph (CT), ultrasonography (US), dual-energy X-ray absorptiometry (DXA), bioelectrical impedance analysis (BIA), skinfold thickness measurements (SFT), and / or air displacement plethysmography (ADP), or any combination thereof. In some embodiments, measurements are taken before, during and / or after administration of the compound to the subject. In some embodiments, administering the compound reduces the amount of a biomarker that positively correlates with muscle loss in a subject relative to the same subject prior to administering the MCIM
[0034] 008930943compound. In some embodiments, administering the MCIM compound increases the amount of a biomarker that positively correlates with muscle regeneration and / or hypertrophy in a subject relative to the same subject prior to administering the MCIM compound. In some embodiments, the biomarker is a muscle protein or a fragment thereof, a transcription factor, and / or a cytokine. In some embodiments, the biomarker is C-terminal agrin fragment (CAF), growth differentiation factor-15 (GDF15), C-reactive protein (CRP) and / or creatine kinase. In some embodiments, the biomarker is PI3K, Klotho, mTORC1, mTORC2, FOXO, MyoD, and / or myogenin.
[0035] In some embodiments, the compound prevents satellite cells from reaching a disease like state, optionally wherein the compound prevents loss of muscle regeneration potential of satellite cells and / or prevents loss of the number of satellite cells compared to prior to the onset of disease or inactivity. In some embodiments, the satellite cells are muscle satellite cells. In some embodiments, the satellite cells are disposed within a muscle effected by muscle loss, fibre atrophy, myositis, fibre degeneration, oedema, and / or development of fat inclusions in the muscle tissue.
[0036] In some embodiments, the compound stimulates expansion of a satellite cell niche microenvironment. In some embodiments, the compound stimulates activation of quiescent satellite cells to generate activated satellite cells. In some embodiments, the compound stimulates proliferation of activated satellite cells. In some embodiments, the compound stimulates differentiation of activated satellite cells to myocytes. In some embodiments, the compound stimulates differentiation of myocytes to myotubes. In some embodiments, the muscle is skeletal muscle and / or smooth muscle.
[0037] In a second aspect, the present disclosure provides a non-therapeutic method of slowing the progression of primary sarcopenia comprising administering to the subject a compound, or a salt, hydrate, or solvate thereof, according to a formula selected from:
[0038]
[0039] 008930943In a third aspect, the present disclosure provides a non-therapeutic method of promoting muscle growth and / or inhibiting muscle loss in a subject comprising administering to the subject a compound, or a salt, hydrate, or solvate thereof, according to a formula selected from:
[0040]
[0041] In some embodiments, the primary sarcopenia, muscle growth, or muscle loss is determined by measuring a biomarker that correlates with ageing. In some embodiments, the biomarker is indicative of chronic systemic inflammation. In some embodiments, the biomarker is GDF15, FGF21 or CAF1, or any combination thereof.
[0042] In some embodiments relating to the compounds for use and the methods as described herein, the compound is a compound selected from compounds of the following formulae, or a pharmaceutically acceptable salt, hydrate, or solvate thereof:
[0043]
[0044] 008930943
[0045]
[0046] 008930943
[0047]
[0048] or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
[0049] In some embodiments, the MCIM compound is selected from compounds of the following formulae:
[0050]
[0051] 008930943
[0052]
[0053] or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
[0054] In some embodiments, the MCIM compound is a compound of the following formula, or a pharmaceutically acceptable salt, hydrate, or solvate thereof:
[0055]
[0056] In some embodiments, the MCIM compound is a compound of the following formula, or a pharmaceutically acceptable salt, hydrate, or solvate thereof:
[0057]
[0058] In some embodiments, the MCIM compound is a compound selected from compounds of the following formula, or a pharmaceutically acceptable salt, hydrate, or solvate thereof:
[0059]
[0060] In some embodiments, the MCIM compound is a compound of the following formula, or a pharmaceutically acceptable salt, hydrate, or solvate thereof:
[0061] 008930943
[0062]
[0063] In some embodiments, the compound for use of any of the above aspects, or the method of any of the above aspects, may cause an increase in a subject’s grip strength compared to prior the subjects grip strength prior to administration with the MCIM compound. Grip strength and / or grip power may be measured according to any suitable method known in the art. For example, grip strength may be measured using a dynamometer. In some embodiments, grip strength and / or grip power may be measured before commencing treatment with an MCIM compound, for example, grip strength and / or grip power may be measured at day 0 of treatment. In some embodiments, grip strength and / or grip power may increase relative to grip strength and / or grip power prior to commencing treatment. For example, an increase in grip strength and / or grip power may be apparent after 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks, 49 weeks, 50 weeks, 51 weeks, or 52 of treatment with the MCIM compound. In some embodiments, treatment with the MCIM compound may result in an increase of at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, or at least 25% compared to grip strength and / or grip power as measured prior to starting treatment with an MCIM compound. In some embodiments, treatment with an MCIM compound may prevent further loss in grip strength and / or grip power compared to grip strength prior to commencing treatment with an MCIM.
[0064] Summary of the Figures
[0065] Embodiments and experiments illustrating the principles of the invention will now be discussed with reference to the accompanying figures in which:
[0066] Figure 1. Histological cross sectional (A) or longitudinal sectional (B) H& E-stained images (x 80 magnification) of muscle fibres from naive mice.
[0067] Figure 2. Histological images of muscle fibres from mouse with collagen-induced arthritis treated with empty vector at x 80 magnification (A) and x 160 magnification (B) showing evidence of myositis, inflammatory infiltrates and fibre atrophy.
[0068] 008930943Figure 3. Histological images (x160 magnification) of muscle fibres from mouse with collagen-induced arthritis treated with either 10 mg / kg of ABD900 (top panel) or an empty vector control (lower panel). Images show an increase in cross-section area of muscle fibres in mice given ABD900. Replicate microscopy images shown in (A) and (B).
[0069] Figure 4. Graphs showing quantitative histopathological scoring of features of muscle degeneration in mice with collagen-induced arthritis treated with ABD900 (left hand panels 0.1, 1 or 10 mg / kg / day), HMC-C-01-A (right hand panels, 10 mg / kg / day) or a vector control (V). Scoring for (A) Myositis, (B) Fibre degeneration / necrosis, (C) Fat inclusions (D) Oedema. Dotted line in Figure 4B shows the value for fibre degeneration in animals at the start of treatment (Vector (V), Day 0 (DO)) or in naive, disease-free animals (Naive). **p<0.01, ***p<0.005, one-way ANOVA vs vector. §§§ p<0.005, one-way ANOVA vs start of treatment (vector, Day 0 (DO).
[0070] Figure 5. Graphs showing quantitative histopathological scoring of features of fibre changes in mice with collagen-induced arthritis treated with ABD900 (left hand panels, 0.1, 1 or 10 mg / kg / day), HMC-C-01-A (right hand panels, 10 mg / kg / day) or a vector control. Scoring for either 0.1, 1 or 10 mg / kg of ABD900 or a vector control. Scoring for (A) Fibre Atrophy, (B) Fibre hypertrophy and (C) muscle fibre cross-sectional area. Dotted lines in Figure 5C, right panel shows the value for % fibres with CSA 1440μM2in animals at the start of treatment (Vector (V), Day 0 (DO)). *** p<0.005, one-way ANOVA.
[0071] Figure 6. Histological images showing an expansion of the progenitor niche in muscles of mice with collagen-induced arthritis treated with 10 mg / kg ABD900 at x80 (upper panel) and x160 (lower panel) magnification.
[0072] Figure 7. Graphs showing quantitative histopathological scoring of features of muscle degeneration and fibre changes in mice with collagen-induced arthritis treated with ABD900 (10 mg / kg / day), the Janus kinase inhibitor, Upadacitinib (3 mg / kg / day, bd) or a vector control. Scoring for Myositis, Fibre atrophy, Fibre hypertrophy and muscle fibre cross-sectional area. * p<0.05, *** p<0.005, one-way ANOVA vs vector, §§§p<0.005, one-way ANOVA vs upadacitinib.
[0073] Figure 8. Graphs showing changes in gastrocnemius and soleus (A) total muscle mass and (B) as a percentage of total bodyweight in mice with collagen-induced arthritis treated with ABD900 (1 or 10 mg / kg / day), HMC-C-01-A (0.1, 1 or 10 mg / kg / day) or a vector control,tp<0.1, *p<0.05, one-way ANOVA vs vector.
[0074] Figure 9. Graphs showing quantitative histopathological scoring of features of muscle degeneration and fibre changes in mice with DSS-induced colitis treated with ABD900 (1, 3 or 10 mg / kg / day), or a vector control. Scoring for Myositis, Fibre atrophy and Fibre hypertrophy. * p<0.05, **p<0.01, *** p<0.005, oneway ANOVA vs vector.
[0075] 008930943Figure 10. Graphs showing median change from baseline in the circulating biomarkers (A) growth differentiation factor 15 (GDF-15), (B) fibroblast growth factor 21 (FGF-21 ) and (C) C-terminal agrin fragment (CAF), in human patients with severe rheumatoid arthritis treated with HMC-C-01-A or placebo for 12 weeks. * p<0.05, *** p<0.005 Wilcoxon rank-signed test vs placebo, modified full analysis set.
[0076] Figure 11. Graph showing the percentage of patients with severe rheumatoid arthritis reporting “no problems” with different aspects of physical function assessed using the HAQ-DI following 12 weeks of treatment with HMC-C-01-A (black bars) or placebo (white bars). AR1 ‘Are you able to stand up from a straight chair?’, AR2 ‘Are you able to get in and out of bed?’, EA1 ‘Are you able to cut your meat?’, WA1 ‘Are you able to walk outdoors on flat ground?’, WA2 ‘Are you able to climb up five steps?’, HY2 ‘Are you able to take a tub bath?’, HY3 ‘Are you able to get on and off the toilet?’, RE1 ‘Are you able to reach and get down a 5 pound object (such as a bag of sugar) from just above your head?’, RE2 ‘Are you able to bend down to pick up clothing from the floor?’, GR1 ‘Are you able to open car doors?’, GR3 ‘Are you able to able to turn faucets on and off?’. § p<0.1, * p<0.05, *** p<0.005, logistic regression model for modified full analysis set.
[0077] Figure 12. Graphs showing quantitative histopathological scoring of features of fibre changes in aged mice at baseline (BL) and at day 84 following daily treatment with vector control, 1 mg / kg, 3 mg / kg or 10 mg / kg MCIM compound. Scoring for (A) Fibre Degeneration / Necrosis, (B) Fat Inclusions, and (C) Oedema. * p<0.05, ** p<0.01, *** p<0.005 vs vehicle. § p<0.05 §§ p<0.01 §§§ p<0.005 vs start of treatment.
[0078] Figure 13. Graph showing quantitative histopathological scoring of features of fibre changes in aged mice at baseline (BL) and at day 84 following daily treatment with vector control, 1 mg / kg, 3 mg / kg or 10 mg / kg MCIM compound. Scoring for percentage of fibres with a cross-sectional area (CSA) greater than 1360 μm2, (B) satellite cells, and (C) percentage of Ki67 positive satellite cells. * p<0.05, ** p<0.01, *** p<0.005 vs vehicle.
[0079] Figure 14. Graphs showing quantitative histopathological scoring of features of fibre changes in aged mice at baseline (BL) and at day 84 following daily treatment with vector control, 1 mg / kg, 3 mg / kg or 10 mg / kg MCIM compound. Scoring for (A) number of satellite cells in myofibre cross-sections, and (B) percentage of Ki67 positive satellite cells. * p<0.05, ** p<0.01, *** p<0.005 vs vehicle. § p<0.05 §§ p<0.01 §§§ p<0.005 vs start of treatment.
[0080] Figure 15. Graphs showing quantitative histopathological scoring of features of fibre changes in aged mice at baseline (BL) and at day 84 following daily treatment with vector control, 1 mg / kg, 3 mg / kg or 10 mg / kg MCIM compound. Scoring for (A) percentage of MHC7 positive Type 1 muscle fibres and (B) percentage of MYH1 positive Type 2 muscle fibres. * p<0.05, ** p<0.01, *** p<0.005 vs vehicle. § p<0.05 §§ p<0.01 §§§ p<0.005 vs start of treatment.
[0081] 008930943Figure 16. Graphs showing change in grip strength aged mice compared to baseline and at (A) day 42 and (B) day 84 following daily treatment with vehicle control, 1 mg / kg, 3 mg / kg or 10 mg / kg MCIM compound. * p<0.05, ** p<0.01, *** p<0.005 vs vehicle. § p<0.05 §§ p<0.01 §§§ p<0.005 vs start of treatment.
[0082] Detailed Description of the Invention
[0083] Aspects and embodiments of the present invention will now be discussed with reference to the accompanying figures. Further aspects and embodiments will be apparent to those skilled in the art. All documents mentioned in this text are incorporated herein by reference.
[0084] Mitochondrial Complex I modulator (MCIM) compounds disclosed herein, and disclosed in WO2024189230 A1, WO2010032009A1, WO / 2020 / 035560, WO / 2020 / 212581, and PCT / EP2024 / 057086 modulate the activity of mitochondrial complex I in a manner that differs from that of conventional complex I inhibitors. MCIM compounds, such as ABD900 and HMC-C-01-A, bind to the lid pocket in the NDUFS2 subunit of mitochondria complex I, specifically at the site of the junction between NDUFS2 and NDUFS7. Inhibition of complex I in this way elicits an adaptive response which directs cell fate choices and elicits damage repair-responses in vivo. When cells are treated with MCIM compound, they are thought to attempt to restore tissue homeostasis by reducing energy-intensive activities such as proliferation.
[0085] Phenotypically, this can control inflammation, alter the activation response of resident cells and desensitizes the microenvironment to the effects of a pro-inflammatory cell infiltrate, and concurrently initiate repair signals in affected tissues, such as in joints. However, it has now surprisingly been found that the MCIM compounds can also affect muscle mass and / or muscle regeneration.
[0086] The present disclosure provides a pharmaceutical composition comprising an MCIM compound as defined herein for use in a method of treating muscle loss, for example cachexia, sarcopenia, muscular atrophy associated with inactivity, or muscle loss associated with muscular dystrophy. The method of treatment may increase or maintain muscle mass, muscle hypertrophy or muscle fibre cross-sectional area. Relatedly, the method of treatment may also reduce or inhibit the rate of muscle loss, muscle fibre atrophy, myositis, fibre degeneration, oedema, fat inclusion size or fat inclusion in the muscle tissue. The effects provided by the MCIM compound may be attributed to the MCIM compound stimulating muscle stem cell (satellite cell) expansion and differentiation, and subsequent muscle regeneration.
[0087] Also provided is a method of treating muscle loss, the method comprising administering an MCIM compound as disclosed herein to a patient. Also provided is the use of an MCIM compound in the manufacture of a medicament for use in treating muscle loss.
[0088] Muscle structure
[0089] MCIM compounds as described herein may be used to treat muscle loss, including but not limited to any of the diseases, disorders or syndromes discussed herein. In general, muscle loss results when muscle regeneration cannot match the rate of muscle protein degeneration and atrophy. In the present
[0090] 008930943application, the inventors disclose for the first time that treatment with MCI M compounds can inhibit the loss of muscle mass and actively stimulate an increase in muscle mass. For example, MCIM compounds can increase muscle hypertrophy and the cross-sectional area of muscle fibres.
[0091] The three major types of muscle tissue are skeletal, cardiac, and smooth muscle. Skeletal muscle cells comprise thousands of elongated muscle fibres, which are formed from the fusion of developmental myoblasts in a process known as myogenesis. The resulting myocytes have multiple myonuclei located along the inside of the cell membrane. T o meet the high energy demands of the muscle tissue, muscle fibres or myofibers have an abundance of mitochondria.
[0092] Muscle fibres are bundled together and wrapped in a connective tissue sheath termed the epimysium. Within the epimysium, muscle fibres are compartmentalised further into fasciculus that are surrounded in connective tissue known as the perimysium. The perimysium comprises primarily of type I and type III collagen fibres and contains nerve endings and small blood vessels. Within the fasciculus, individual muscle fibres are contained within an additional network of connective tissue known as the endomysium which contains blood vessels, lymphatic vessels and nerves that supply the muscle fibres. The connective tissue of the perimysium and endomysium merge together and extend beyond the length of muscle fibres to form tendons that attach to bones or connective tissues of other muscles.
[0093] There is a positive correlation with the cross-sectional area of muscle fibres and muscle strength, with greater cross-sectional area corresponding to stronger muscle tissue. During muscle loss, cross-sectional area can be reduced. Following damage or stress, skeletal muscle can be regenerated by proliferation of muscle stem cells known as satellite cells.
[0094] In inflammatory myopathies and myositis specifically (which is characterised by inflammation of muscle tissue) there is an increase in inflammatory infiltrates within the connective tissues of the perimysium and endomysium. Inflammatory infiltrates include T-cells, B-cells and plasma cells, but can also include perimysial macrophages.
[0095] Unlike skeletal muscle, smooth muscle is controlled by the autonomic nervous system and functions involuntarily i.e not through conscious movement. It is found in the walls of internal organs with hollow cores such as blood vessels, the gastrointestinal tract, bladder, and uterus. Smooth muscle cells are spindle shaped with one central nucleus and together form sheets of tissue giving a non-striated (smooth) appearance. Smooth muscle stem cells, known as pericytes, allow smooth muscle cells to regenerate and repair after damage, and are considered to have the greatest regenerative capacity among the three major muscle types.
[0096] Unlike skeletal muscle and smooth muscle, it is widely thought that human cardiac muscle tissue cannot regenerate following injury, although in recent years it has been suggested that card io myocytes have a regenerative capacity, albeit limited.
[0097] At its broadest, muscle mass refers to the amount of muscle that makes up a subject’s body composition. Muscle mass can be associated with an increase in muscle fibre cross sectional area, muscle fibre volume, muscle tissue thickness and / or muscle strength. An increase in muscle mass can result from
[0098] 008930943muscle fibre hypertrophy. Muscle hypertrophy is an increase in the size of muscle cells or fibres. Muscle hypertrophy can be in response to various stimuli. Muscle hypertrophy can result from an increase in the cytoplasmic volume of muscle cells (known as sarcoplasmic hypertrophy) or an increase in myofibril size, known as myofibrillar hypertrophy.
[0099] Muscle Loss
[0100] The MCIM compounds disclosed herein may be used to treat muscle loss caused by a broad range of aetiologies. That is, the muscle loss to be treated may be sarcopenia, cachexia, muscular atrophy associated with inactivity, or muscle loss associated with a muscular dystrophy (Evans, 2010).
[0101] Progression of muscle loss is characterised by a loss of muscle mass and may comprise a reduction in cross sectional area of muscle fibres, an increase in myositis, an increase in muscle fibre degeneration, an increase in fat inclusions in muscle tissue, an increase in oedema and / or muscle fibre atrophy.
[0102] In view of the above, in a first aspect of the present invention, the disclosure provides an MCIM inhibitor for use in the treatment of muscle loss. In some embodiments, the muscle loss is selected from sarcopenia, cachexia, muscle atrophy associated with inactivity and / or muscle loss associated with muscular dystrophy.
[0103] The muscle loss to be treated can be sarcopenia. ‘Primary sarcopenia’ is characterised by muscle loss associated with aging without any known cause and symptoms include fatigue, difficulty with daily activities, slow walking speed, and increased risk of falls age-related sarcopenia. It results from the decline of skeletal muscle tissue and is recognised as one of the main reasons for loss of mobility and independence in older adults. In some embodiments, the muscle loss to be treated may be primary sarcopenia.
[0104] Sarcopenia associated with chronic diseases such as autoinflammatory, autoimmune, fibrotic, cardiovascular, neurological or metabolic conditions is known as ‘secondary sarcopenia’. In some embodiments, the muscle loss to be treated may be secondary sarcopenia. By way of example, secondary sarcopenia is associated with inflammatory bowel disease (IBD), with more than one third of IBD patients thought to suffer from sarcopenia, which can result from malnutrition brought on by chronic inflammation of the intestine (Nardone et al., 2021). IBD includes ulcerative colitis (UC) and Crohn’s disease (CD). Secondary sarcopenia also affects up to 66% of patients with rheumatoid arthritis, 31% patients with cardiovascular disease and a significant proportion of patients with obesity, where it is referred to as sarcopenic obesity. Neurological decline, hormonal changes, inflammatory pathway activation, declines in activity, chronic illness, fatty infiltration, and poor nutrition, have all been shown to be contributing factors to secondary sarcopenia development (Walston 2012).
[0105] Primary sarcopenia may be exacerbated by chronic diseases such as autoinflammatory, autoimmune, fibrotic, cardiovascular, neurological or metabolic conditions.
[0106] 008930943Sarcopenia of old age frequently co-presents with osteopenia or osteoporosis, where it is known as osteosarcopenia. Similarly, sarcopenia is often associated with obesity, defined by high body fat percentage, in a condition known as sarcopenic obesity. An individual may be considered obese if their body mass index (BMI) is over 30, although this can vary with ethnicity. Secondary sarcopenia and sarcopenic obesity specifically may also be associated with MASLD and / or MASH.
[0107] Moreover, drugs used for therapeutic or preventive purposes are also known to induce secondary sarcopenia (Kuzuya et al., 2024). This can be consequence of the drug adversely affecting the mechanisms that maintain the balance of muscle protein synthesis and degradation. For example, several studies report secondary sarcopenia resulting from treatment with anti-diabetic drugs (Zhang et al., 2021). Certain steroids have also been associated with muscle loss, for example chronic use of glucocorticoids, which are a class of corticosteroids, is known to induce myopathy (Pereira et al., 2011). Relatedly, in some embodiments, the muscle loss is sarcopenia. In some embodiments, the muscle loss is sarcopenia associated with ageing. In some embodiments, the muscle loss is primary sarcopenia. In some embodiments, the sarcopenia or secondary sarcopenia is associated with inflammation. In some embodiments, the inflammation is associated with the musculoskeletal system and / or the digestive system.
[0108] In some embodiments, the sarcopenia is induced by, exacerbated by or associated with a disease or disorder. In some embodiments, the muscle loss is secondary sarcopenia. In some embodiments, the secondary sarcopenia is induced by, exacerbated by or associated with an autoimmune disease, a metabolic condition, a fibrotic disease, and / or a neurological disease. In some embodiments, the fibrotic disease is idiopathic pulmonary fibrosis (IPF). In some embodiments, the secondary sarcopenia induced by, exacerbated by or associated with an autoimmune disease is a fibrotic disease and / or a neurological disease.
[0109] In some embodiments, the secondary sarcopenia induced by, exacerbated by or associated with an autoimmune disease, condition or disorder. In some embodiments, the sarcopenia is induced by, exacerbated by or associated with arthritis, rheumatoid arthritis, IBD, cardiovascular disease and / or obesity. In some embodiments, the sarcopenia is induced by, exacerbated by or associated with rheumatoid arthritis and / or IBD. In some embodiments, the sarcopenia is induced by, exacerbated by or associated with arthritis.
[0110] In some embodiments, the muscle loss is sarcopenia that co-presents or is associated with osteopenia or osteoporosis. In some embodiments, the muscle loss is osteosarcopenia.
[0111] In some embodiments, the muscle loss is sarcopenia that co-presents or is associated with obesity. In some embodiments, the muscle loss is sarcopenic obesity. In some embodiments, the sarcopenia is associated with a metabolic condition or disorder. In some embodiments, the sarcopenia is associated with fat build up and / or damage to the liver. In some embodiments, the sarcopenia is associated with MASLD and / or MASH.
[0112] 008930943In some embodiments, the muscle loss is induced, exacerbated and / or associated with a treatment, treatment strategy, therapeutic, medicine and / or drug.
[0113] In some embodiments, the sarcopenia is induced, exacerbated and / or associated with a treatment, treatment strategy, therapeutic, medicine and / or drug. In some embodiments, the muscle loss is drug-induced sarcopenia. In some embodiments, the secondary sarcopenia is drug-induced sarcopenia. In some embodiments, the sarcopenia is induced, exacerbated or associated with anti-diabetic drugs. In some embodiments, the sarcopenia is induced or associated with treatment using anti-diabetic drugs. In some embodiments, the anti-diabetic drug is a glucagon-like peptide-1 receptor agonist (GLP-1 RA). In some embodiments, the sarcopenia is induced, exacerbated or associated with steroid usage. In some embodiments, the steroid is a corticosteroid or an anabolic-androgenic steroid. In some embodiments, the steroid is a glucocorticoid. In some embodiments, the steroid is an anabolic steroid or an androgen.
[0114] Cachexia
[0115] The muscle loss to be treated can be cachexia. Cachexia is a systemic metabolic muscle wasting disorder that develops as a consequence of a range of diseases including cancer, HIV / AIDS, chronic obstructive pulmonary disease (COPD) and rheumatoid arthritis (RA). Symptoms of cachexia include unexplained weight loss, muscle loss, fatigue, weakness, and anorexia. Cachexia may be associated with skeletal muscle loss, smooth muscle loss and / or cardiac muscle loss. Cachexia cannot be fully reversed with improved nutrition and is thought to be driven by an increase in muscle protein degradation leading to a decrease in muscle fibre size and volume. A number of factors contribute to progression of cachexia, including changes in inflammatory mediators, tissue homeostasis mediators, and metabolic mediators, which are discussed in (Ferrer et al., 2023). In patients with cancer, Cachexia is thought to result from the upregulation of systemic inflammation and catabolic stimuli, which leads to protein synthesis inhibition and increased muscle catabolism (Setiawan et al., 2023).
[0116] In patients with RA, cachexia is referred to as rheumatoid cachexia and occurs in a third of RA patients. The exact aetiology of rheumatoid cachexia is unclear but factors including pro-inflammatory cytokine-induced catabolism, insulin resistance, insufficient protein ingestion and reduced anabolism are thought to contribute to muscle loss (Ollewagen et al., 2021). Moreover, continual RA-associated inflammation results in depletion of the capacity for regeneration and repair of the satellite cell niche (Ollewagen et al., 2021).
[0117] Cachexia can be accelerated or worsened by certain treatments, for example chemotherapeutics (Campelj et al., 2021 ), anti-diabetic drugs (Zhang, 2021 ), or RA treatments (Ollewagen et al., 2021 ). That is, Cachexia can be drug induced or exacerbated by drugs.
[0118] In some embodiments the muscle loss is cachexia. In some embodiments, the muscle loss is cachexia associated with disease. In some embodiments, the muscle loss is drug-induced cachexia. In some embodiments the cachexia is associated with cancer, pancreatic cancer, stomach cancer, oesophageal
[0119] 008930943cancer, colorectal cancer, chronic obstructive pulmonary disease (COPD), heart failure, chronic kidney disease, HIV / AIDS, sepsis, emphysema, organ failure, Alzheimer’s disease, dementia, congestive heart failure (CHF), chronic kidney disease cystic fibrosis, arthritis, rheumatoid arthritis, Crohn's disease, tuberculosis, colitis, or any disease with associated muscle loss. In some embodiments, the cachexia is associated with cancer. In some embodiments, the cachexia is associated with arthritis. In some embodiments, the arthritis is rheumatoid arthritis. In some embodiments, the muscle loss is associated with IBD. In some embodiments, the muscle loss is associated with IBD and / or RA. In some embodiments, the IBD is colitis.
[0120] In some embodiments, the cachexia is induced, exacerbated and / or associated with a treatment, treatment strategy, therapeutic, medicine and / or drug.
[0121] In some embodiments, the cachexia is induced, exacerbated or associated by cancer therapy. In some embodiments, the cachexia is induced, exacerbated or associated with chemotherapy, immunotherapy, radiotherapy, surgery, vaccination and / or hormone therapy.
[0122] In some embodiments, the cachexia is induced, exacerbated or associated with anti-diabetic drugs. In some embodiments, the cachexia is induced or associated with treatment using anti-diabetic drugs. In some embodiments, the anti-diabetic drug is a glucagon-like peptide-1 receptor agonist (GLP-1 RA). In some embodiments, the cachexia is induced, exacerbated or associated with steroid usage. In some embodiments, the steroid is a corticosteroid or an anabolic-androgenic steroid. In some embodiments, the steroid is a glucocorticoid. In some embodiments, the steroid is an anabolic steroid or an androgen. In some embodiments, the cachexia is associated with a treatment, treatment strategy, therapeutic, medicine and / or drug. In some embodiments, the cachexia is induced and / or exacerbated by a treatment, treatment strategy, therapeutic, medicine and / or drug.
[0123] In some embodiments, the cachexia is induced, exacerbated and / or associated with a treatment, treatment strategy, therapeutic, medicine and / or drug.
[0124] Other cases of muscle loss
[0125] The muscle loss to be treated can be associated with inactivity, which can be independent or associated with aging or the disease related metabolic changes that drive cachexia. Muscle loss can occur during extended periods of bedrest or immobilization, which may be unavoidable for a range of reasons including disease that would otherwise not affect muscle function. However, inactivity is not thought to affect protein degradation, unlike cachexia.
[0126] Relatedly, in some embodiments, the muscle loss is muscular atrophy associated with inactivity. In some embodiments, inactivity is caused and / or worsened by a disease or disorder. In some embodiments, inactivity is caused and / or exacerbated by a disease or disorder that would otherwise not affect muscle structure and / or function.
[0127] 008930943Muscle loss and degeneration is also a consequence of neuromuscular diseases such as muscular dystrophy. Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy and is caused by a hereditary mutation in the dystrophin gene. Muscle fibre degeneration in subjects with DMD causes progressive weakness and muscle wasting. Therapeutic approaches to treat muscular dystrophies have focused on restoring defective gene function and methods to harness muscle stem cell regeneration (Mackenzie et al., 2021 and Biressi et al., 2020).
[0128] Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is also a neuromuscular condition associated with progressive muscle weakness and atrophy. In ALS, muscle breakdown occurs due to the degeneration of motor neurons in the motor cortex and spinal cord, breaking down neuron to muscle communication and leading to the loss of voluntary muscle control and eventually paralysis. ALS is considered a multisystemic and multifactorial disease accelerated by physiological alterations of other cell types and skeletal muscle, with dismantlement of neuromuscular junctions now thought to occur before motor neuron degeneration (Scaricamazza et al., 2021). Accordingly, a range of therapeutic approaches targeting skeletal muscles have been developed to treat ALS (reviewed in Scaricamazza et al., 2021).
[0129] Neuromuscular disorders include, for example, ALS, muscular dystrophy, multiple sclerosis, MS, myopathy, peripheral neuropathy, Charcot-Marie-Tooth disease, myasthenia gravis, myositis (including polymyositis and dermatomyositis) and spinal muscular atrophy. While there are no cures for neuromuscular disorders, ameliorating the associated degeneration of muscle fibres is a promising approach to slow disease development.
[0130] Relatedly, in some embodiments the muscle loss is associated with a neuromuscular condition. In some embodiments, the sarcopenia is associated with a neuromuscular condition. In some embodiments, the cachexia is associated with a neuromuscular condition. In some embodiments the muscle loss is not associated with a neuromuscular disorder.
[0131] In some embodiments, the muscle loss is associated with Amyotrophic Lateral Sclerosis (ALS), muscular dystrophy, multiple sclerosis (MS), myopathy, peripheral neuropathy, Charcot-Marie-Tooth disease, myasthenia gravis, myositis (including polymyositis and dermatomyositis) and spinal muscular atrophy. In some embodiments, the muscle loss is associated with muscular dystrophy and / or amyotrophic lateral sclerosis (ALS). In some embodiments, the muscular dystrophy is Duchenne muscular dystrophy (DMD).
[0132] Treatment of Muscle Loss
[0133] Chronic muscle loss refers to persistent loss of muscle mass or a gradual decline in muscle mass across an extended period of time, for example longer than six months. Acute muscle loss, for example, acute sarcopenia, can occur within six months of a stress-induced event e.g. the contraction of a disease or sudden hospitalisation. Relatedly, in some embodiments, the muscle loss is chronic muscle loss. In some embodiments, the muscle loss is acute muscle loss. In some embodiments, the muscle loss is acute and / or chronic muscle loss.
[0134] 008930943In certain aspects of the present invention, the disclosure provides MCIM for use in the treatment or prevention muscle loss associated with a disease in which the muscle loss is pathologically implicated. A disease / disorder in which muscle loss is ‘pathologically implicated’ may be e.g. a disease / disorder in which loss of muscle mass, strength, volume and / or fibre cross-sectional area is positively associated with onset, development or progression of the disease / disorder, and / or severity of one or more symptoms of the disease / disorder. Muscle loss may be present in any organ / tissue which is affected by the disease (e.g. an organ / tissue in which the symptoms of the disease / disorder manifest). The extent of muscle loss may be determined as a reduction of mass, strength, volume, fibre cross-sectional area etc in the relevant organ / tissue. Accordingly, treatment for muscle loss can be quantified by an increase in muscle mass, or the inhibition of further muscle loss.
[0135] Relatedly, in some embodiments, administering the MCIM compound increases muscle mass. In some embodiments, administering the MCIM compound increases muscle mass of the subject compared to muscle mass of the subject prior to commencing treatment with the MCIM compound. In some embodiments, the MCIM compound maintains muscle mass of the subject. In some embodiments, the MCIM compound maintains muscle mass of the subject compared to the muscle mass of the subject prior to commencing treatment with the MCIM compound. In some embodiments, the MCIM compound inhibits muscle mass loss. In some embodiments, the MCIM compound inhibits muscle mass loss of the subject compared to the rate of muscle mass loss of the subject prior to commencing treatment with the MCIM compound. In some embodiments, the MCIM compound reduces the rate of loss of muscle mass in a subject. In some embodiments, the MCIM compound reduces the rate of loss of muscle mass in a subject compared to the rate of loss of muscle mass in the subject prior to commencing treatment with the MCIM compound. In some embodiments, the muscle is skeletal muscle and / or smooth muscle. In accordance with various aspects of the present invention, in some embodiments, the muscle is selected from skeletal muscle, smooth muscle and cardiac muscle. In some embodiments, the muscle is skeletal muscle. In some embodiments, the muscle is skeletal muscle and / or cardiac muscle. In some embodiments, the muscle is skeletal muscle and / or smooth muscle. In some embodiments, the MCIM has an anabolic effect on muscle mass. In some embodiments, the MCIM compound increases the mass of the soleus and / or gastrocnemius muscle.
[0136] In some embodiments, administering the MCIM compound increases and / or maintains muscle hypertrophy and / or the cross-sectional area of muscle fibres of the subject compared to the subject prior to commencing treatment with the compound. In some embodiments, muscle hypertrophy and / or the cross-sectional area of muscle fibres is measured in a subject by histopathological assessment, semi-quantitative and / or quantitative grading of key histological parameters of a sample taken from the subject. Any means of histopathological assessment and / or semi-quantitative grading of key histological parameters may be used, for example, those described in Example 1 and 2 of the present application. In some embodiments, the sample is a biopsy specimen.
[0137] A reduction in muscle mass is a consequence of a reduction in the number and / or volume of muscle fibres and occurs during cachexia, sarcopenia and / or muscular atrophy associated with inactivity. Muscle
[0138] 008930943loss is also associated with muscle fibre atrophy, myositis, fibre degeneration, oedema, fat inclusion size and / or fat inclusion number in the muscle tissue, or any combination thereof, compared to the subject prior to commencing treatment with the compound. Semi-quantitative grading of these key histological parameters can be performed using a five-point scale: 0 - no significant findings; 1 - minimal, usually focal lesions; 2 - moderate, focal; 3 - moderate, multi-focal or diffuse; 4 - marked.
[0139] Muscle fibre atrophy refers to a decrease in muscle mass, and fibre cross-sectional area at the histological level. It can result in a reduction in force production, exercise capability and / or accelerates the onset of fatigue. Muscle fibre atrophy can be scored on the basis of shrinkage of single fibres or fibre groups and expansion of endomysium zones. An increase in fat inclusions (droplets) size and number within the fibre sheath is often associated with muscle atrophy and decline. In contrast, at the histological level, expansion of fibres or fibre blocks with shrinkage or loss of clear endomysium or perimysium zones is indicative of muscle fibre atrophy.
[0140] Myositis relates to inflammation of muscle tissue. At the histological level, infiltration of immune cells into muscle tissue can be indicative of myositis. This can be seen as inflammatory foci invading the muscle block, usually in perimysium and endomysium. Myositis can occur with other symptoms such as pain and fatigue, which is known as idiopathic inflammatory myopathy (IIM). Myositis is often associated with autoimmune diseases involving chronic inflammation of the muscles.
[0141] Muscle fibre degeneration refers to the breakdown and / or rupturing of muscle fibres. At the histological level, degenerated muscle fibres can be identified by single fibre lesions, cell swelling, hypereosinophilia, vacuolation, loss of striation, fragmentation, rupture of fibers and the presence of retraction caps, which are cavities at the end of muscle fibres. The extent of degeneration can vary along a muscle fibre.
[0142] Extensive fibre degeneration can lead to myofiber necrosis.
[0143] Oedema, or edema, in muscle is swelling of muscle tissue caused by an increase in fluid within the tissue. The fluid can be free water. At the histological level, oedema is characterised by fluid inclusions within fibres or affecting perimysium zones, the expansion of interstitial tissue, clear to pale eosinophilic material that separates and surrounds individual myofibers. Muscle oedema can cause muscle weakness, fatigue and pain.
[0144] In some embodiments, administering the MCIM compound inhibits muscle fibre atrophy, myositis, fibre degeneration, oedema, development of fat inclusions in the muscle tissue, or any combination thereof, in the subject. In some embodiments, administering the MCIM compound inhibits muscle fibre atrophy, myositis, fibre degeneration, oedema, development of fat inclusions in the muscle tissue, or any combination thereof, compared to the subject prior to commencing treatment with the MCIM compound. In some embodiments, administering the MCIM compound arrests muscle fibre atrophy, myositis, fibre degeneration, oedema, development of fat inclusions in the muscle tissue, or any combination thereof, in the subject. In some embodiments, administering the MCIM compound arrests muscle fibre atrophy, myositis, fibre degeneration, oedema, development of fat inclusions in the muscle tissue, or any combination thereof, compared to the subject prior to commencing treatment with the MCIM compound.
[0145] 008930943In some embodiments, muscle fibre atrophy, myositis, fibre degeneration, oedema, development of fat inclusions in the muscle tissue, or any combination thereof, is measured in a subject by histopathological assessment, semi-quantitative grading, and / or quantitative grading of key histological parameters of a sample taken from the subject. Any means of histopathological assessment and / or semi-quantitative grading of key histological parameters may be used, for example, those described in Example 1 and 2 of the present application. In some embodiments, the sample is a biopsy specimen.
[0146] Biomarkers of muscle loss
[0147] Easily accessible and non-invasive blood-derived biomarkers are an invaluable tool for monitoring progression of disease. C-terminal agrin fragment (CAF) has been widely used as a neuromuscular junction (NMJ)-related biomarker of muscle dysfunction and can be used to diagnose sarcopenia (reviewed in Monti et al., 2023 and Fatima et al., 2025, Pratt et al., 2024). During neuromuscular-junction damage and breakdown, the c-terminal of agrin protein is cleaved, leading to an increase in CAF release into the blood. Thus, CAF is a reliable biomarker to evaluate muscle loss, including sarcopenia, associated with both ageing and disease. It correlates with measurements of muscle mass and muscle function and is also reflective of neuromuscular junction integrity. CAF is also higher in individuals with muscle wasting conditions, such as DMD and ALS diabetes, COPD, chronic heart failure and stroke, and in pancreatic and colorectal cancer cachectic patients.
[0148] Growth differentiation factor-15 (GDF15) is a systemic biomarker for reporting cellular aging and systemic inflammation. GDF15 stress-responsive cytokine, and as a result increases under cellular stress and with disease. GDF15 is a marker of integrated stress which is an emerging biomarker of skeletal muscle dysfunction in conditions like sarcopenia and muscle wasting (Chiariello et al., 2024, De Paepe et al., 2022). Because aging is accompanied by the gradual development of chronic systemic inflammation (inflamm-ageing), in addition to chronic disease, GDF15 can be used as an accurate biomarker for aging (Liu et al., 2021, Chen et al., 2025).
[0149] Fibroblast growth factor 21 (FGF21) is peptide hormone which regulates several metabolic processes including energy expenditure, metabolic adaptation and the regulation of muscle mass (Tezze et al., 2019). FGF21 is also a biomarker of health span and longevity.
[0150] Other biomarkers for muscle loss include C-reactive protein (CRP) and creatine kinase (CK).
[0151] Interestingly, CK in the blood is indicative of acute muscle damage, however reduced levels of CK are associated with muscle wasting or loss (Bermejo et al., 2022).
[0152] The term “biomarker” as used herein refers to an indicator, for example a predictive and / or prognostic indicator, which can be detected in a sample (e.g., a gene or protein). The biomarker may serve as an indicator of a particular condition or disorder (e.g., sarcopenia) characterised by certain molecular, pathological, histological, and / or clinical features. Biomarkers can be a gene or a collection of genes. Biomarkers include, but are not limited to, polynucleotides (e.g., DNA, and / or RNA), polynucleotide copy number alterations (e.g., DNA copy numbers), polypeptides, polypeptide and polynucleotide modifications (e.g. posttranslational modifications), carbohydrates, and / or glycolipid-based molecular markers.
[0153] 008930943In general, the concentration and / or amount of a biomarker for a particular condition positively or negatively correlates with the progression, development and / or treatment of a disease or condition. That is, a biomarker ‘for’ a disease or condition refers to a biomarker that can be measured to determine the presence, absence (e.g. after treatment), or development of the particular disease condition. A biomarker may be used to report on the presence, absence, or development of more than one disease or condition. Any method of measuring protein expression levels known in the art may be used to determine the presence or absence of a biomarker. For example, biomarker protein expression can be determined using western blot, enzyme-linked immunosorbent assay (ELISA), immunoprecipitation, immunohistochemistry (IHC), flow cytometry (e.g., fluorescence-activated cell sorting (FACS™)), immunofluorescence, radioimmunoassay, dot blotting, immunodetection methods, HPLC, surface plasmon resonance, optical spectroscopy, mass spectrometry, liquid chromatography- mass spectrometry (LC-MS), nephelometry, aptamer technology, and HPLC.
[0154] Where the biomarker to be measured is a gene or a nucleic acid, expression of the one or more genes can be determined qualitatively and / or quantitatively based on any method known in the art, for example whole genome sequencing, polymerase chain reaction (PCR), including quantitative real time PCR (qRT-PCR) amplification type detection methods, (e.g, branched DNA, SISBA, TMA), RNASeq, microarray analysis, gene expression profiling, whole-genome sequencing (WGS), and / or serial analysis of gene expression (“SAGE”), direct digital counting of nucleic acids (e.g., Nanostring nCounter), immunohistochemistry (“IHC”), Western blot analysis, immunoprecipitation, molecular binding assays, ELISA, ELIFA, fluorescence activated cell sorting (“FACS”), MassARRAY, proteomics, biochemical enzymatic activity assays, in situ hybridization (ISH), fluorescence in situ hybridization (FISH), Southern analysis, Northern analysis, as well as any one of the wide variety of assays that can be performed by protein, gene, and / or tissue array analysis.
[0155] Biomarkers may be measured in a number of types of sample, for example, synovial tissue sample, a synovial fluid sample, serum, plasma, blood, vitreous fluid, lymph fluid, follicular fluid, seminal fluid, amniotic fluid, milk, whole blood, blood-derived cells, urine, cerebro-spinal fluid, saliva, sputum, tears, perspiration, mucus, or any combination thereof
[0156] Relatedly, in some embodiments, administering the MCIM compound reduces the amount of a biomarker for muscle loss. In some embodiments, administering the MCIM compound reduces the amount of a biomarker that correlates with muscle loss in a sample from a subject. In some embodiments, administering the MCIM compound reduces the amount of a biomarker that positively correlates with muscle loss in a subject relative to the same subject prior to administering the MCIM compound. In some embodiments, administering the MCIM compound reduces the amount of a biomarker that positively correlates with muscle loss in a subject relative to a subject suffering from muscle loss not having been administered the MCIM compound. In some embodiments, administering the MCIM compound increases the amount of a biomarker that negatively correlates with muscle loss in a subject relative to a subject suffering from muscle loss not having been administered the MCIM compound.
[0157] 008930943In some embodiments, administering the MCIM compound reduces the amount of a biomarker for sarcopenia. In some embodiments, administering the MCIM compound reduces the amount of a biomarker that positively correlates with sarcopenia in a subject relative to the same subject prior to administering the MCIM compound. In some embodiments, administering the MCIM compound reduces the amount of a biomarker that positively correlates with sarcopenia in a subject relative to a subject suffering from sarcopenia not having been administered the MCIM compound. In some embodiments, administering the MCIM compound increases the amount of a biomarker that negatively correlates with sarcopenia in a subject relative to a subject suffering from sarcopenia not having been administered the MCIM compound.
[0158] In some embodiments, administering the MCIM compound reduces the amount of a biomarker for cachexia. In some embodiments, administering the MCIM compound reduces the amount of a biomarker that positively correlates with cachexia in a subject relative to the same subject prior to administering the MCIM compound. In some embodiments, administering the MCIM compound reduces the amount of a biomarker that correlates with cachexia in a subject relative to a subject suffering from cachexia not having been administered the MCIM compound. In some embodiments, administering the MCIM compound increases the amount of a biomarker that negatively correlates with cachexia in a subject relative to a subject suffering from cachexia not having been administered the MCIM compound.
[0159] In some embodiments, the biomarker is a polypeptide or protein. In some embodiments, the biomarker is a muscle protein or a fragment thereof, a transcription factor and / or a cytokine. In some embodiments, the biomarker for muscle loss, sarcopenia, or cachexia is C-terminal agrin fragment (CAF), growth differentiation factor-15 (GDF15), C-reactive protein (CRP), fibroblast growth factor 21 (FGF21), and / or creatine kinase. In some embodiments, the biomarker for muscle repair is PI3K, mTORC1, mTORC2, FOXO, MyoD, and / or myogenin.
[0160] In some embodiments, the presence or absence of a biomarker is measured in a sample taken from a patient who is receiving or has received treatment with an MCIM compound. In some embodiments, the sample is a blood, plasma, and / or serum sample. In some embodiments, the MCIM compound reduces or increases the concentration of a biomarker in a sample obtained from a subject.
[0161] Muscle regeneration
[0162] Proliferation and differentiation of muscle stem cells known as satellite cells or myosatellites is essential for muscle repair. Satellite cells exist in a microenvironment niche in a quiescent state and proliferate sporadically to replace muscle myofibres damaged by activity. The satellite cell niche is located below the basal lamina and the sarcolemma and sits adjacent to the plasma membrane of myofibres. Within the niche exist a range of other cell types including T cells, B cells, neutrophils and Schwann cells, tenocytes and smooth muscle-mesenchymal cells that can facilitate signalling activation of satellite cells. Major muscle damage or atrophy disrupts the satellite cell niche, which triggers signalling cascades that stimulate expansion of the niche through activation of quiescent satellite cells and subsequent
[0163] 008930943proliferation. Signalling factors include a plethora of transcription factors such as those from the Pax7 family (reviewed in Sousa-Victor et al., 2022). Activated satellite cells subsequently differentiate into myoblast and myocytes, which fuse at the site of damage. This results in muscle fibre regeneration and muscle repair.
[0164] Proliferating satellite cells have an increased energy demand and during the transition from quiescence to proliferation, satellite cells experience a metabolic switch from fatty acid oxidation to glycolysis (Ryall et al. Cell Stem Cell 2015, 16(2), 171 - 183). This adjustment reduces intracellular NAD+ levels, resulting in epigenetic changes that ultimately lead to muscle gene transcription. The increased availability of ATP from glycolysis is thought to allow satellite cells to quickly react to the increased energy demand of the activated state. Additionally, during satellite cell activation, genes associated with the TCA cycle are also upregulated, suggesting an increase in aerobic respiration also contributes to meeting the higher energy demand of activated satellite cells (Yartseva, V. et al Development 2019, 146, dev174177). Furthermore, signalling mediated by metabolic sensors and effectors, such as PI3K, mTORC1, mTORC2, FOXO, MyoD, and myogenin transcription factors are thought to promote satellite cell state transition (reviewed in in Sousa- Victor et al., 2022). Accordingly, transcription factors PI3K, mTORC1, mTORC2, FOXO, MyoD, and / or myogenin may be used as biomarkers to assess muscle regeneration, hypertrophy and / or development.
[0165] Upon differentiation, satellite cells revert to oxidative phosphorylation for ATP production, which is enabled by an increase in mitochondrial mass and electron transport capacity.
[0166] In the present disclosure, the inventors found that administering MCIM compound expanded the size of the satellite cell niche, which is indicative of satellite cell proliferation and muscle regeneration.
[0167] In some embodiments, the MCIM compound stimulates activation of quiescent satellite cells to generate activated satellite cells. In some embodiments, the MCIM compound stimulates proliferation of activated satellite cells. In some embodiments, the MCIM compound stimulates activation of quiescent satellite cells and proliferation of activated satellite cells. In some embodiments, the MCIM compound stimulates expansion of a satellite cell niche microenvironment. In some embodiments, the MCIM compound stimulates differentiation of activated satellite cells. In some embodiments, the MCIM compound stimulates differentiation of activated satellite cells to myocytes. In some embodiments, the MCIM compound stimulates differentiation of myocytes. In some embodiments, the MCIM compound stimulates differentiation of myocytes to myotubes.
[0168] In some embodiments, the MCIM compound promotes migration of activated satellite cells and / or a differentiated satellite cell to a site of damage within the muscle tissue. In some embodiments, the MCIM compound promotes migration of activated satellite cells and / or a differentiated satellite cell to a damaged muscle fibre and / or myofiber. In some embodiments, the MCIM compound promotes fusion of a differentiated satellite cell to a damaged muscle fibre and / or myofiber.
[0169] In some embodiments, the MCIM compound promotes migration of myocytes and / or myotubes to a site of damage within the muscle tissue. In some embodiments, the MCIM compound promotes migration of
[0170] 008930943myocytes and / or myotubes to a damaged muscle fibre and / or myofiber. In some embodiments, the MCIM compound promotes fusion of a myocytes and / or myotube to a damaged muscle fibre and / or myofiber. In some embodiments, the muscle damage is the result of muscle atrophy. In some embodiments, the damage is the result of sarcopenia, cachexia and / or atrophy associated with inactivity. In some embodiments, the damage is the result of physical damage.
[0171] In some embodiments, administering the MCIM compound increases the amount of a biomarker for muscle regeneration and / or hypertrophy. In some embodiments, administering the MCIM compound increases the amount of a biomarker that correlates with muscle regeneration and / or hypertrophy in a sample from a subject. In some embodiments, administering the MCIM compound increases the amount of a biomarker that positively correlates with muscle regeneration and / or hypertrophy in a subject relative to the same subject prior to administering the MCIM compound. In some embodiments, administering the MCIM compound increases the amount of a biomarker that positively correlates with muscle regeneration and / or hypertrophy in a subject suffering from muscle loss relative to a subject suffering from muscle loss not having been administered the MCIM compound.
[0172] In some embodiments, administering the MCIM compound increases the amount of a biomarker that positively correlates with muscle regeneration and / or hypertrophy in a subject suffering from sarcopenia relative to the same subject prior to administering the MCIM compound. In some embodiments, administering the MCIM compound increases the amount of a biomarker that positively correlates with muscle regeneration and / or hypertrophy in a subject suffering from sarcopenia relative to a subject suffering from sarcopenia not having been administered the MCIM compound.
[0173] In some embodiments, administering the MCIM compound increases the amount of a biomarker that positively correlates with muscle regeneration and / or hypertrophy in a subject suffering from cachexia relative to the same subject prior to administering the MCIM compound. In some embodiments, administering the MCIM compound increases the amount of a biomarker that positively correlates with muscle regeneration and / or hypertrophy in a subject suffering from cachexia relative to a subject suffering from cachexia not having been administered the MCIM compound.
[0174] In some embodiments, the subject is suffering from muscle loss, sarcopenia and / or cachexia.
[0175] In some embodiments, the biomarker is a muscle protein or a fragment thereof, a transcription factor and / or a cytokine. In some embodiments, the biomarker is PI3K, mTORC1, mTORC2, FOXO, MyoD, and / or myogenin.
[0176] To maintain capacity for tissue regeneration, satellite cell populations require continual renewal. To ensure this is the case, during the muscle regeneration process a subset of proliferating cells do not differentiate but instead self-renew to reconstitute the quiescent satellite cell pool for future muscle repair. In old age and in disease, the regeneration potential of satellite cells is progressively lost and a decline in satellite cell number and functionality is observed. A disease-like state refers to a satellite cell population with reduced muscle regeneration potential and / or number of satellite cells compared to prior to the onset of disease or inactivity. Relatedly, in some embodiments, administering the MCIM compound prevents
[0177] 008930943satellite cells from reaching a disease like state. In some embodiments, the MCIM compound inhibits reduction in satellite cell number. In some embodiments, the MCIM compound promotes satellite cell renewal.
[0178] Clinical scoring methods
[0179] Several methodologies are known in the art and may be used to assess patients suffering from a range of musculoskeletal diseases or disorders and age-related disabilities, such as sarcopenia and cachexia. Examples of scoring methods which may be used to assess patients from said musculoskeletal diseases and disorders include the “Health Assessment Questionnaire” (HAQ-DI), “Strength, assistance with walking, rising from a chair, climbing stairs, and falls” (SARC-F) questionnaire, and the Cachexia score (CASCO), each of which is described in more detail below. In addition, visual inspections may be employed to assess a change in muscle mass. MCIM compounds disclosed herein may improve patient scores as measured by any suitable scoring method or methods.
[0180] That is, in some embodiments, administering an MCIM compound improves a patients score as measured by any suitable scoring method or methods. In some embodiments, the scoring method is by visual Inspection, the Health Assessment Questionnaire Disability Index (HAQ-DI), Strength, assistance with walking, rising from a chair, climbing stairs, and falls (SARC-F) questionnaire and / or the Cachexia score (CASCO) method.
[0181] It will be appreciated that it is not necessary outside of clinical trials for each patient treated with the MClMs as disclosed herein to undergo or undertake one or more the aforementioned clinical assessments before and / or after treatment. Such an approach may be unduly burdensome on patients and physicians. Assessment of an individual patient’s response to treatment is down to the discretion of the treating physician.
[0182] Visual inspection
[0183] Overall muscle mass and symmetry can be used as an indicator of muscle wasting and atrophy. For example, subjects undergoing muscle loss / wasting may be observed to have, for example, hollowing of the temples (wasting of the temporalis), flattening of the interosseous muscles in the area between the thumb and index finger, squaring of the shoulders (loss of deltoids), prominence of the infrascapular fossa (loss of pectoral and deltoid muscles), prominence of the scapula (loss of trapezius and deltoid), prominence of rib cage (loss of latissimus dorsi and intercostal muscles), and loss of muscle mass of the upper leg (quadriceps) or calf (gastrocnemius) (Ottery F, 2001, incorporated herein by reference).
[0184] Subjects treated with an MCIM as described herein may demonstrate a reversal of the observed muscle wasting / muscle loss in any one of the aforementioned muscles / muscle groups. Subjects treated with an MCIM as described herein may demonstrate an inhibition of further loss of muscle mass following commencement of treatment. Subjects treated with an MCIM as described herein may demonstrate an increase in muscle mass, for example, in any one or more of the aforementioned muscles / muscle groups.
[0185] 008930943HAQ-DI
[0186] The Health Assessment Questionnaire (HAQ) Disability Index (DI) may be carried out as described in Wolfe F et al (1994) and “THE HEALTH ASSESSMENT QUESTIONNAIRE (HAQ) DISABILITY INDEX (DI) OF THE CLINICAL HEALTH ASSESSMENT QUESTIONNAIRE (VERSION 96.4)”, both of which is hereby incorporated by reference in their entirety. The HAQ-DI method includes questions related to whether a patient has difficulty in performing a range of everyday activities, the answer to which are indicative of the level of functional disability experienced by a subject. This methodology can be used to assess functional disability, including patients suffering from RA and / or age-related functional decline / disability, including functional decline / disability associated with muscle loss. Briefly, the HAQ comprises 8 sections relating to dressing, arising, eating, walking, hygiene, reach, grip, and activities. Each section comprises 2 or 3 questions, with scoring for each section being given on a scale of 0 (without any difficulty) to 3 (unable to do). The score given to each section is the highest score given for any given question in each section. The 8 scores of the 8 sections are summed and divided by 8 (or if, for example, only 7 sections are completed by a subject divided by 7). A score of <1 indicates mild disability, a score of 1-2 indicates moderate disability and a score of >2 indicates severe disability (Krishnan et al., 2004). Subjects treated with an MCIM as described herein may demonstrate a decrease in the HAQ-DI score of >0.22, indicating the subject has achieved a minimally important clinical difference (MCID). Subjects treated with an MCIM as described herein may also demonstrate a decrease in the HAQ-DI score of >0.68, indicating the subject has achieved a critical difference (i.e. the minimum change that can be reliably discriminated from random long-term variations). Subjects treated with an MCIM as described herein may achieve functional remission, indicated by a HAQ-DI score of <0.5, and in some cases a subject may achieve a population normative score of <0.25.
[0187] In some embodiments, administering the MCIM compound to a subject reduces the HAQ-DI score of a subject. In some embodiments, administering the MCIM compound to a subject reduces the HAQ-DI score by >0.22 and / or >0.68. In some embodiments, administering the MCIM compound to a subject reduces the HAQ-DI score to <0.5 and / or <0.25.
[0188] In some embodiments, administering the MCIM compound to subjects increases the proportion of a population of subjects experiencing no functional problems, as determined by the HAQ-DI method. In some embodiments, administering the MCIM compound to a subject reduces the HAQ-DI population normative score to <0.5 and / or <0.25.
[0189] SARC-F Questionnaire
[0190] The SARC-F questionnaire may be carried out as described in Malmstrom TK and Morley JE (2013) and Malmstrom TK et al (2016), which are hereby incorporated by reference in its entirety. Briefly, the SARC-F questionnaire comprises five questions related to strength, assistance in walking, rising from a chair, climbing stairs and falls as shown in Table 1, below:
[0191] 008930943Table 1: SARC-F Scoring
[0192]
[0193] A score equal to or greater than 4 is predictive of sarcopenia and poor outcomes. Subjects treated with an MCIM as described herein may have a reduced SARC-F score compared to the subjects SARC-F score prior to treatment with the MCIM. Subjects treated with an MCIM as described herein may have a SARC-F score reduced from 10, 9, 8, 7, 6, 5 or 4 following treatment with an MCIM. Subjects treated with an MCIM as described herein may maintain a SARC-F score following treatment. In some embodiments, administering the MCIM compound to a subject reduces the SARC-F score of the subject from 10, 9, 8, 7, 6, 5 or 4. In some embodiments, administering the MCIM compound to a subject reduces the SARC-F score of the subject from 10, 9, 8, 7, 6, 5 or 4 by 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0194] Grip strength
[0195] Grip strength is a biomarker for overall health, functional status and mortality. Average grip strength varies with age, with younger men and women typically having an average grip strength of 46 kg and 29 kg, respectively. Grip strength tends to decrease with age and correlates with muscle loss. Average grip strength decreases to 39 kg for men and 23.5 kg for women by the age of 60. Grip strength may be measured using any suitable assay or clinical assessment criteria known to the person skilled in the art. For example, a dynamometer reading may be taken to assess grip strength (e.g. using a Jamar Hydraulic Dynamometer). A “low strength” threshold associated with sarcopenia may be determined as <27 kg for men and <16 kg for women (lee et al 2020). Grip strength may be measured using any of the methods described in Lee et al 2020, which is hereby incorporated by reference. In some embodiments, treatment
[0196] 008930943with an MCIM compound of a subject who has a “low strength” threshold, may result in an increase in grip strength, for example an increase in grip strength above the “low strength” threshold. In some embodiments, treatment with an MCIM compound may prevent loss in grip strength.
[0197] Grip power
[0198] Grip power may be measured as described in Ojeda AH., et al 2021, which is hereby incorporated by reference. For example, grip power may be determined as follows:
[0199] Subjects complete a standardised 5-minute warm-up, actively mobilising the wrist and finger joints. For assessment, each subject stands facing forward and laterally to the supports, grasping a dumbbell fitted with a linear encoder in the test hand. The dumbbell is positioned so that its centre aligns with the interphalangeal joints of the middle and ring fingers and the distal interphalangeal joints of the index and little fingers. The testing arm is fully extended (elbow at 180°), shoulder relaxed, and wrist in a neutral position. Subjects perform finger flexion with thumb opposition to generate a handgrip, lifting the dumbbell vertically as quickly as possible, without additional movement from the shoulder, elbow, or wrist.
[0200] The protocol comprises incremental loading, with dumbbell weights increasing from 1 to 10 kg in 1 kg increments. Rest periods are 30 seconds between series and 1 minute between limbs. The number of repetitions per set is determined by the mean velocity: four repetitions for 60-50 cm s“1, three for 49-30 cm s“1, two for 29-20 cm s“1, and one for 19-1 cm s“1. Grip velocity and power may be measured using a CHRONOJUMP® linear encoder and associated software (Version 1.4.6.0, Barcelona, Spain). Mean velocities and powers for each load are recorded and averaged per set. Maximum individual grip power is determined by constructing a load-power curve and applying linear regression (y = ax + b) to averaged power values across all loads.
[0201] The Cachexia Score (CASCO)
[0202] The CACO is a validated clinical scoring system for the severity of cachexia and is described in Argiles JM et al (2011), which is hereby incorporated by reference in its entirety. The CASCO is based primarily on four test components: 1) body weight loss and composition (BWC); 2) inflammation / metabolic disturbances / immunosuppression (IMD), 3) physical performance (PHP), 4) anorexia (ANO), and 5) quality of life (QoL). The following parameters (Table 2) may be measured and / or monitoring for change over the time course of treatment using any suitable assay or clinical assessment criteria known to the person skilled in the art:
[0203] Table 2: CASCO Scoring
[0204]
[0205] 008930943
[0206]
[0207] 008930943
[0208]
[0209] A score of 0-25, 26-50, 51-75 and 76-100 is classified as mild, moderate, severe and terminal, respectively. Subjects treated with an MCIM as described herein may have a reduced CASCO score compared to the subjects CASCO score and / or classification prior to treatment with the MCIM. Subjects treated with an MCIM as described herein may have a CASCO classification reduced from terminal, severe, moderate or mild following treatment with an MCIM. In some embodiments, administering a MCIM compound to a subject reduces the CASCO score from mild moderate, severe or terminal. In some
[0210] 008930943embodiments, administering a MCIM compound to a subject reduces the CASCO score from mild moderate, severe or terminal to no score, mild, moderate and / or severe. Subjects treated with an MCIM as described herein may maintain a CASCO score and / or classification following treatment.
[0211] Prophylaxis
[0212] As disclosed above, the MCIM compounds disclosed herein may find use in the treatment or prevention of muscle loss associated with a variety of pathological conditions discussed above. ‘Prevention’ as used herein will be understood to include inhibition of muscle loss and / or inhibition of further muscle loss. That is to say, in some embodiments, the MCIM compounds may be administered to inhibit progression of further muscle loss. In some embodiments, the MCIM compounds may be administered prior to detection of muscle loss thereby preventing muscle loss - i.e. in some embodiments, the MCIM compound may be administered as a prophylactic treatment. For example, in some embodiments, the subject may have or be suspected of having a disease or disorder which predisposes the subject to muscle loss.
[0213] Non-therapeutic uses and methods
[0214] Muscle loss may be non-pathological. For example, muscle loss due to reduced activity may result in a non-pathological decrease in muscle mass. " Non-pathological" means not relating to, or not caused by, a disease or abnormal condition of the body. For example, a non-pathological decrease in muscle mass may be the result of reduced exercise but which does not result in functional physical decline associated with disability, and / or associated with the natural decrease in muscle mass associated with ageing. Thus, in some embodiments, the disclosure further provides non-therapeutic uses of MCIM compounds for inhibiting muscle loss and / or increasing muscle mass.
[0215] MCIM Compounds
[0216] Exemplary MCIM compounds suitable for use in the methods of treatment disclosed herein may be described by the following formula, as disclosed in WO2010 / 032009 which is hereby incorporated by reference in its entirety:
[0217]
[0218] wherein:
[0219] -A is independently:
[0220]
[0221] 008930943-Ar is independently phenyl, pyridinyl, or pyrimidinyl; and
[0222] p is independently an integer from 0 to 3;
[0223] and wherein:
[0224] q is independently an integer from 0 to 3;
[0225] and wherein:
[0226] -RSNis independently -H or saturated aliphatic C1-4alkyl;
[0227] and wherein:
[0228] -DQ is independently -D1-Q1or -D2=O;
[0229] -D1- is independently cyclopentane-di-yl, cyclohexane-di-yl, cycloheptane-di-yl,
[0230] bicy clo[3.1.1 ]heptane-di-yl, or bicyclo[3.2.1]octane-di-yl, and is optionally substituted with one or more groups -RD;
[0231] -D2= is independently cyclopentane-yl-ylidene, cyclohexane-yl-ylidene, cycloheptane-yl-ylidene, bicyclo[3.1.1]heptane-yl-ylidene, or bicyclo[3.2.1]octane-yl-ylidene, and is optionally substituted with one or more groups -RD;
[0232] each -RDis independently selected from -F, -Cl, -Br, -I, -RDD, -CF3, -OH, -ORDD, -NH2, -NHRDD, and -NRDD2; and
[0233] each -RDDis independently saturated aliphatic C1-4alkyl;
[0234] and wherein -Q1is independently selected from:
[0235]
[0236] wherein:
[0237] each -R1Nis independently -H, -RCN, or -RCF;
[0238] each -R2Nis independently -H, -RCN, or -RCF;
[0239] each -RCNis independently saturated aliphatic C1-4alkyl;
[0240] 008930943each -RCFis independently saturated aliphatic C1-4fluoroalkyl;
[0241] or:
[0242] -NR1NR2Nis independently azetidino, pyrrolidino, imidazolidino, pyrazolidino, piperidino, piperazino, morpholino, thiomorpholino, azepino, or diazepino, each optionally substituted with one or more groups independently selected from saturated aliphatic C1-4alkyl;
[0243] -R1Ais independently -H, -Rc, or -RF; and
[0244] -R2Ais independently -H, -Rc, or -RF;
[0245] or -R1Aand -R2Atogether form a saturated aliphatic C2-4alkylene group;
[0246] -R1Bis independently -H, -Rc, or -RF; and
[0247] -R2Bis independently -H, -Rc, or -RF;
[0248] or -R1Band -R2Btogether form a saturated aliphatic C2-4alkylene group;
[0249] or -R1Band -R2Btogether form =0;
[0250] -R3Ais independently -H, -Rc, or -RF; and
[0251] -R4Ais independently -H, -Rc, or -RF;
[0252] or -R3Aand -R4Atogether form a saturated aliphatic C2-4alkylene group;
[0253] -R5Ais independently -H, -Rc, -RF, or -RJ; and
[0254] -R6Ais independently -H, -Rc, or -RF;
[0255] or -R5Aand -R6Atogether form a saturated aliphatic C2-4alkylene group;
[0256] -R3Bis independently -H, -Rc, or -RF; and
[0257] -R4Bis independently -H, -Rc, or -RF;
[0258] or -R3Band -R4Btogether form a saturated aliphatic C2-4alkylene group;
[0259] -R5Bis independently -H, -Rc, -RF, -OH, or -OR0; and
[0260] -R6Bis independently -H, -RC, or -RF;
[0261] or -R5Band -R6Btogether form a saturated aliphatic C2-4alkylene group;
[0262] each -RCis independently saturated aliphatic C1-4alkyl;
[0263] each -RFis independently saturated aliphatic Ci-4fluoroalkyl;
[0264] -ROis independently saturated aliphatic C1-4alkyl;
[0265] -RJis independently -NH2, -NHRJN1, -NRJN12, or -NRJN2RJN3;
[0266] each -RJN1is independently saturated aliphatic C1-4alkyl; and
[0267] 008930943-NRJN2RJN3is independently azetidino, pyrrolidino, imidazolidino, pyrazolidino, piperidino, piperazino, morpholino, thiomorpholino, azepino, or diazepino, each optionally substituted with one or more groups independently selected from saturated aliphatic C1-4alkyl;
[0268] and wherein each -Rxis independently:
[0269] -F, -Cl, -Br, -I,
[0270] -Rxx,
[0271] -OH, -ORXX,
[0272] -SH, -SRXX,
[0273] -CF3, -OCF3, -SCF3,
[0274] -NH2, -NHRXX, -NRXX2, -NRYYRZZ,
[0275] -C(=O)RXX, -OC(=O)RXX,
[0276] -C(=O)OH, -C(=O)ORXX,
[0277] -C(=O)NH2, -C(=O)NHRXX, -C(=O)NRXX2, -C(=O)NRYYRZZ,
[0278] -OC(=O)NH2, -OC(=O)NHRXX, -OC(=O)NRXX2, -OC(=O)NRYYRZZ,
[0279] -NHC(=O)RXX, -NRXXC(=O)RXX,
[0280] -NHC(=O)ORXX, -NRXXC(=O)ORXX,
[0281] -NHC(=O)NH2, -NHC(=O)NHRXX, -NHC(=O)NRXX2, -NHC(=O)NRYYRZZ, -NRXXC(=O)NH2, -NRXXC(=O)NHRXX, -NRXXC(=O)NRXX2, -NRXXC(=O)NRYYRZZ,
[0282] -CN,
[0283] -NO2,
[0284] -S(=O)2NH2, -S(=O)2NHRXX, -S(=O)2NRXX2, -S(=O)2NRYYRZZ,
[0285] -S(=O)RXX, -S(=O)2RXX, -OS(=O)2RXX, -S(=O)2OH, or -S(=O)2ORXX;
[0286] wherein:
[0287] each -RXXis independently saturated aliphatic C1-6alkyl, phenyl, or benzyl, wherein said phenyl and benzyl are optionally substituted with one or more groups selected
[0288] from: -F, -Cl, -Br, -I, -CF3, -OCF3, -RXXX, -OH, -ORXXX, or -SRXXX, wherein each -RXXXis independently saturated aliphatic C1-4alkyl; and
[0289] each -NRYYRZZis independently azetidino, pyrrolidino, imidazolidino, pyrazolidino, piperidino, piperazino, morpholino, thiomorpholino, azepino, or diazepino, each optionally substituted with one or more groups independently selected from saturated aliphatic C1-4alkyl.
[0290] 008930943In some embodiments, -Ar is independently phenyl or pyridinyl; p is independently an integer from 1 to 3; q is independently 0 or 1; -RSNis -H; -DQ is -D1-Q1; -D1- is cyclohexane-di-yl and is optionally substituted with one group -RD; -RDis -RDD; and -RDDis methyl; each -Rxis
[0291] independently: -F, -Cl, -Br, -RXX, -ORXX, -CF3, or -CN; each -RXXis independently methyl and -Q1is:
[0292]
[0293] In some embodiments:
[0294]
[0295] q is independently 0 or 1;
[0296] -RSNis -H;
[0297] -DQ is:
[0298]
[0299] -Rxis independently -F or -Cl;
[0300] -RX2is independently -F, -Cl, -CN, or -CF3;
[0301] -RX4is independently -F, -Cl, or -CN.
[0302] The following exemplary MCIM compounds suitable for use in the methods of treatment disclosed herein may be described by the following chemical structures, as disclosed in W02020 / 035560 A1, which is hereby incorporated by reference in its entirety.
[0303] In some embodiments, the compound is a compound, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, of the following formula:
[0304]
[0305] defined in claim 1 of W02020 / 035560 A1, wherein:
[0306] —X- is independently -CH= or -N=;
[0307] -R1is independently -H or -R1X;
[0308] -R1Xis independently -F, -Cl, -R1C, -R1F, or -CN;
[0309] -R1Cis independently saturated linear or branched Ci-3alky I;
[0310] -R1Fis independently saturated linear or branched Ci-3fluoroalkyl;
[0311] 008930943-R2is independently -H or -R2X;
[0312] -R2Xis independently -F, -Cl, -R2C, -R2F, or -CN;
[0313] -R2Cis independently saturated linear or branched Ci-3alky I;
[0314] -R2Fis independently saturated linear or branched Ci-3fluoroalkyl;
[0315] -R3is independently -H or -R3X;
[0316] -R3Xis independently -F, -Cl, -R3C, -R3F, or -CN;
[0317] -R3Cis independently saturated linear or branched Ci-3alky I;
[0318] -R3Fis independently saturated linear or branched Ci-3fluoroalkyl;
[0319] -R4is independently -H or -R4X;
[0320] -R4Xis independently -F, -Cl, -R4C, -R4F, or -CN;
[0321] -R4Cis independently saturated linear or branched Ci-3alky I;
[0322] -R4Fis independently saturated linear or branched Ci-3fluoroalkyl;
[0323] -R5is independently -H or -R5X;
[0324] -R5Xis independently -F, -R5C, or -R5F;
[0325] -R5Cis independently saturated linear or branched Ci-3alky I;
[0326] -R5Fis independently saturated linear or branched Ci-3fluoroalkyl;
[0327] -R6is independently -H or -R6X;
[0328] -R6Xis independently -F, -R6C, or -R6F;
[0329] -R6Cis independently saturated linear or branched Ci-3alky I; and
[0330] -R6Fis independently saturated linear or branched Ci-3fluoroalkyl;
[0331] or -R5and -R6, taken together with the carbon atom to which they are attached, form saturated Cs-ecycloalkyl.
[0332] Claim 1 of W02020 / 035560 A1 is hereby incorporated by reference. Furthermore, W02020 / 035560 A1 is hereby incorporated by reference in its entirety.
[0333] The following exemplary MCIM compounds suitable for use in the methods of treatment disclosed herein may be described by the following chemical structures, as disclosed in WO2020 / 212581 A1, which is hereby incorporated by reference in its entirety.
[0334] In some embodiments, the compound is a compound, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, of the following formula:
[0335]
[0336] as defined in claim 1 of W02020 / 212581 A1, wherein: -X= is independently -CH= or -N=;
[0337] “m” is independently 0, 1, 2, or 3;
[0338] 008930943each -RAis independently -F, -Cl, -RAC, -RAF, or -CN;
[0339] -RACis independently saturated linear or branched C1-3alkyl;
[0340] -RAFis independently saturated linear or branched Ci-3fluoroalkyl;
[0341] “n” is independently 0, 1, or 2;
[0342] each -RBis independently -F, -Cl, -RBC, -RBF, or -CN;
[0343] -RBCis independently saturated linear or branched Ci-3alky I;
[0344] -RBFis independently saturated linear or branched Ci-3fluoroalkyl;
[0345] -R1is independently -H or -R1X;
[0346] -R1Xis independently -F, -R1C, or -R1F;
[0347] -R1Cis independently saturated linear or branched Ci-3alky I;
[0348] -R1Fis independently saturated linear or branched Ci-3fluoroalkyl;
[0349] -R2is independently -H or -R2X;
[0350] -R2Xis independently -F, -R2C, or -R2F;
[0351] -R2Cis independently saturated linear or branched Ci-3alky I;
[0352] -R2Fis independently saturated linear or branched Ci-3fluoroalkyl;
[0353] or -R1and -R2, taken together with the carbon atom to which they are attached, form saturated Cs-ecycloalkyl;
[0354] -R3is independently -H or -R3X;
[0355] -R3Xis independently -R3Cor -R3F;
[0356] -R3Cis independently saturated linear or branched Ci-3alky I;
[0357] -R3Fis independently saturated linear or branched Ci-3fluoroalkyl;
[0358] -R4is independently -R4C, -R4CC, or -N(R4N1)(R4N2);
[0359] -R4Cis independently saturated linear or branched C1-6alkyl;
[0360] -R4CCis independently saturated Cs-ecycloalkyl;
[0361] -R4N1is independently -H or -R4N1C;
[0362] -R4N1Cis independently saturated linear or branched C1-4alkyl;
[0363] -R4N2is independently -H or -R4N2C; and
[0364] -R4N2Cis independently saturated linear or branched C1-4alkyl,
[0365] or -N(R4N1)(R4N2) is independently azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl, and is optionally substituted with one or more saturated linear or branched Chalky I groups.
[0366] Claim 1 of W02020 / 212581 A1 is hereby incorporated by reference. Furthermore, WO2020 / 212581 A1 is hereby incorporated by reference in its entirety.
[0367] 008930943The following exemplary MCIM compounds suitable for use in the methods of treatment disclosed herein may be described by the following chemical structures, as disclosed in WO2014 / 207445, which is hereby incorporated by reference in its entirety:
[0368]
[0369] / V-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide
[0370]
[0371] / V-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide The MCIM compound may be selected from compounds of the following formulae, or a pharmaceutically acceptable salt, hydrate, or solvate thereof (for convenience, collectively referred to herein as “HMC compounds”):
[0372]
[0373] 008930943
[0374]
[0375] 008930943
[0376]
[0377] Note that the substituents on one side of the cyclohexyl ring (i.e., -OH and -CH3on the right-hand side) may be positioned “trans" / “cis" or “cis" / “trans" with respect to the rest of the molecule (that is, on the cyclohexyl ring to which they attached, with respect to the rest of the compound which is attached at the para position of the cyclohexyl ring).
[0378]
[0379] Unless otherwise indicated, it is intended that all such conformations are encompassed by a reference to a compound that does not specify a particular conformation.
[0380] The compound may be in the “trans-OH" conformation, as in, for example, the following compounds:
[0381]
[0382] 008930943
[0383]
[0384] Alternatively, the compound may be in the “c / s-OH” conformation, as in, for example, the following compounds:
[0385] 008930943
[0386]
[0387] 008930943
[0388]
[0389] Note also that the cyclohexane ring may take a “chair”, “boat”, or “twist” conformation, and that interconversion between the conformations is possible. Unless otherwise indicated, it is intended that all such conformations (e.g., “chair”, “boat”, “twist”, “OH is axial”, “OH is equatorial”, etc.) are encompassed by a reference to a compound that does not specify a particular conformation.
[0390] In some embodiments, the compound has the following formula:
[0391]
[0392] In some embodiments, the compound has the following formula:
[0393]
[0394] In some embodiments, the compound has the following formula:
[0395]
[0396] Patient Selection
[0397] The MCIM compounds for use in the methods of the present invention may be used to treat or prevent muscle loss in any subject in need thereof. Subjects to be treated may be selected based on symptoms characteristic of muscle loss, for example a reduction in muscle mass, muscle fatigue, muscle weakness, muscle numbness, tingling feeling in muscles, frailty, weight loss, loss of appetite, balancing issues or any other symptom known in the art.
[0398] Subjects selected for treatment based on a loss of muscle mass may be identified using any known muscle mass measuring technique and / or clinical scoring system. Measurements may be taken between
[0399] 008930943two or more time points, and the reduction in muscle mass determined. Techniques to measure muscle mass are familiar to those skilled in the art and include, for example, ultrasonography, magnetic resonance imaging (MRI), computed tomograph (CT), ultrasonography (US), dual-energy X-ray absorptiometry (DXA), bioelectrical impedance analysis (BIA), skinfold thickness measurements (SFT), and / or air displacement plethysmography (ADP). Such techniques may also be used to further characterise muscle loss and evaluate changes in muscle hypertrophy, muscle fibre atrophy, myositis, fibre degeneration, oedema, fat inclusion size and / or fat inclusion in muscle tissue before, during and / or after treatment with an MCIM compound. That is, measurements may be taken between two or more time points before, during and after treatment with an MCIM compound, and the rate of mass loss determined following treatment with an MCIM compound.
[0400] Histological methods known to the skilled person can also be used to evaluate muscle tissue characteristics. Cross sections of muscle tissue samples can be prepared using Hematoxylin and Eosin (H& E) staining to visualise and evaluate size and structure characteristics of muscle fibres. For example, a reduction in fibre cross sectional area relative to a control is indicative of muscle fibre atrophy and muscle loss in a subject, while an increase in immune cell infiltration to the connective tissue of the endomysium and perimysium is a feature of myositis. H& E staining may also be used to visualise the satellite cell niche, in which satellite cells can be identified by their close proximity with each other and centrally located nuclei. Immunostaining can also be utilised to visualise regenerating satellite cells, for example through observation of Pax7 expressing cells.
[0401] In some embodiments, muscle mass is measured in a subject prior to, during, and / or following treatment with an MCIM compound. In some embodiments, muscle mass is measured in a subject prior to, during, and / or following administration of an MCIM compound. In some embodiments, muscle mass is measured using ultrasonography, magnetic resonance imaging (MRI), computed tomograph (CT), ultrasonography (US), dual-energy X-ray absorptiometry (DXA), bioelectrical impedance analysis (BIA), skinfold thickness measurements (SFT), and / or air displacement plethysmography (ADP), or any combination thereof. In some embodiments, muscle mass is measured using ultrasonography, magnetic resonance imaging (MRI), computed tomograph (CT), ultrasonography (US), dual-energy X-ray absorptiometry (DXA), bioelectrical impedance analysis (BIA), skinfold thickness measurements (SFT), and / or air displacement plethysmography (ADP), or any combination thereof prior to, during, and / or following administration of an MCIM compound or treatment with an MCIM compound. Measurements may be repeated over the course of treatment as determined to be necessary by the attending physician.
[0402] In some embodiments, muscle mass, muscle hypertrophy, muscle fibre atrophy, myositis, fibre degeneration, oedema, fat inclusion size and / or fat inclusion number is measured in a subject prior to, during, and / or following administration of an MCIM compound. In some embodiments, muscle mass, muscle hypertrophy, muscle fibre atrophy, myositis, fibre degeneration, oedema, fat inclusion size and / or fat inclusion number is measured using ultrasonography, magnetic resonance imaging (MRI), computed tomograph (CT), ultrasonography (US), dual-energy X-ray absorptiometry (DXA), bioelectrical impedance
[0403] 008930943analysis (BIA), skinfold thickness measurements (SFT), and / or air displacement plethysmography (ADP), or any combination thereof, prior to, during, and / or following administration of an MCIM compound. In some embodiments, muscle mass, muscle hypertrophy, muscle fibre atrophy, myositis, fibre degeneration, oedema, fat inclusion size and / or fat inclusion number is measured upto 1 year, up to 11 months, up to 10 months, up to 9 months, up to 8 months, up to 7 months, up to 6 months, up to 5 months, up to 4 months, up to 3 months, up to 2 months, up to 4 weeks, up to 3 weeks, up to 2 weeks, up to 1 week, up to 6 days, up to 5 days, up to 4 days, up to 3 days, up to 2 days, 1 day prior to the commencement of treatment with an MCIM compound. In some embodiments, muscle mass, muscle hypertrophy, muscle fibre atrophy, myositis, fibre degeneration, oedema, fat inclusion size and / or fat inclusion number is measured up to 1 year, up to 11 months, up to 10 months, up to 9 months, up to 8 months, up to 7 months, up to 6 months, up to 5 months, up to 4 months, up to 3 months, up to 2 months, up to 4 weeks, up to 3 weeks, up to 2 weeks, up to 1 week, up to 6 days, up to 5 days, up to 4 days, up to 3 days, up to 2 days, 1 day following the commencement of treatment with an MCIM compound. In some embodiments, muscle mass, muscle hypertrophy, muscle fibre atrophy, myositis, fibre degeneration, oedema, fat inclusion size and / or fat inclusion number is measured up to 1 year, up to 11 months, up to 10 months, up to 9 months, up to 8 months, up to 7 months, up to 6 months, up to 5 months, up to 4 months, up to 3 months, up to 2 months, up to 4 weeks, up to 3 weeks, up to 2 weeks, up to 1 week, up to 6 days, up to 5 days, up to 4 days, up to 3 days, up to 2 days, 1 day after treatment with an MCIM compound is terminated.
[0404] In some in some embodiments, the subject to be treated is identified as suffering from muscle loss by visual inspection of the muscle mass of the subject. In some in some embodiments, the subject to be treated is identified as suffering from muscle loss by ultrasonography, magnetic resonance imaging (MRI), computed tomograph (CT), ultrasonography (US), dual-energy X-ray absorptiometry (DXA), bioelectrical impedance analysis (BIA), skinfold thickness measurements (SFT), and / or air displacement plethysmography (ADP), or any combination thereof.
[0405] In some in some embodiments, the subject to be treated is identified as suffering from muscle loss through assessment using of a scoring method associated with muscle loss, for example the HAQ-DI, SARC-F and / or CASCO scoring method. In some in some embodiments, the subject to be treated is identified as suffering from muscle loss by achieving a HAQ-DI score of equal to or greater than 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9 or 3. In some in some embodiments, the subject to be treated is identified as suffering from muscle loss by achieving a SARC-F score of equal to or greater than 4, 5, 6, 7, 8, 9 or 10. In some in some embodiments, the subject to be treated is identified as suffering from muscle loss by achieving a CASCO score of mild, moderate, severe and / or terminal. In some in some embodiments, the subject to be treated is identified by having a BMI over 30.
[0406] In some embodiments, the subject to be treated is identified as suffering from muscle loss by measuring the amount of biomarker. In some embodiments, the level of a biomarker is measured in a sample taken from the subject, preferably a blood sample. In some embodiments, the biomarker positively or negatively
[0407] 008930943correlates with muscle damage and / or muscle loss. The biomarker may be any biomarker disclosed herein. In some embodiments, the biomarker is a polypeptide or protein. In some embodiments, the biomarker is a muscle protein or a fragment thereof, a transcription factor and / or a cytokine. In some embodiments, the biomarker for muscle loss, sarcopenia, or cachexia is C-terminal agrin fragment (CAF), growth differentiation factor-15 (GDF15), C-reactive protein (CRP) and / or creatine kinase. In some embodiments, the biomarker for muscle repair is PI3K, mTORC1, mTORC2, FOXO, MyoD, and / or myogenin.
[0408] Muscle damage / loss can be evaluated through measing muscle response and / or electrical activity following nerve stimulation by electromyography (EMG). Surface EMG (sEMG) is increasingly used for assessing and detecting muscle loss, for example sarcopenia (Leone et al., 2025). Relatedly, in some embodiments, the subject to be treated is identified as suffering from muscle loss by electromyography (EMG), preferably surface EMG.
[0409] Pharmaceutical compositions
[0410] The MCIM compounds disclosed herein may be in the form of a medicament or pharmaceutical composition. The medicaments or pharmaceutical composition may be formulated for administration by a number of routes, including but not limited to, parenteral i.e. non-oral route (for example, by injection: subcutaneous, intravenous, intra-arterial, intramuscular, or intratumoral; by topical or intradermal; by inhalation or intranasal; or by rectal), and peroral i.e. oral route. The medicaments and compositions may be formulated in a solid, semi-solid, or liquid dosage form. The pharmaceutical compositions according to this invention may be delivered by a route which facilitates exposure in the systemic circulation or by a route or method which gives rise to localised, targeted, delivery of the active compounds to a selected region in the body. The pharmaceutical compositions according to this invention may also be administered to humans or animals.
[0411] Administration is preferably in a "therapeutically effective amount", this being sufficient to show benefit to the individual. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of the disease being treated. For example, the rate of release of the active compounds from the pharmaceutical composition may be immediate, sustained, extended, controlled, pulsatile or follow a pattern that is optimal for the intended therapeutic application. The frequency of dosing can be fixed or variable depending on the rate of drug release, the required level in the systemic circulation or at the target site to provide the desired therapeutic effect. Prescription of treatment, e.g. decisions on dosage etc., is within the responsibility of physicians and other medical doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in Remington’s Pharmaceutical Sciences, 23rdEdition, 2020, pub. Lippincott, Williams & Wilkins. Relatedly, in some embodiments, a therapeutically effective amount of the MCIM compound is used in the treatment or prevention of muscle loss.
[0412] 008930943Pharmaceutical compositions may be prepared using a pharmaceutically acceptable “carrier” composed of materials, also known as excipients, that are generally considered safe and pharmacologically inert. " Pharmaceutically acceptable" refers to molecular entities and compositions that are "generally regarded as safe - GRAS", e.g., that are physiologically tolerable and do not typically produce adverse or untoward effects when administered to a human. In some embodiments, this term refers to molecular entities and compositions approved by a regulatory agency of the US federal or a state government, as the GRAS list under section 204(s) and 409 of the Federal Food, Drug and Cosmetic Act, that is subject to premarket review and approval by the FDA or similar lists, the U. S. Pharmacopeia or another generally recognised pharmacopeia for use in animals, and more particularly in humans.
[0413] The term “carrier” refers to excipients that serve one or more functions in the pharmaceutical compositions, for example, as diluents, binders, lubricants, glidants, disintegrants, solubilisers or solubility enhancers, stabilisers, preservatives, taste-masking or taste-modifying agents, flavourant, and / or colourant. The pharmaceutical compositions, when formulated as a solid dosage form, may further be uncoated or coated with an outer layer to impart aesthetic features, physical protection, enhance the physical and / or chemical stability of the active compounds or other constituents of the pharmaceutical compositions, and / or alter the rate of dissolution and release of the active compounds from the pharmaceutical compositions. The pharmaceutical compositions, when formulated as a parenteral injectable dosage form, may additionally contain aqueous or non-aqueous solvents, co-solvent mixtures, buffering agents, surfactants, tonicity modifying agents, chelating agents, pH modifiers, viscosity modifiers, and / or suspending agents. The pharmaceutical compositions, when formulated as a parenteral dosage form for inhalation, may additionally contain particle carriers for the pulmonary delivery of the active compounds, absorption penetration enhancers, and / or propellants, dependent on the inhalation delivery device to be used. Those with skill in the art are familiar with such pharmaceutical carriers, and excipients therein, and methods of compounding these carriers and excipients into pharmaceutical compositions. Suitable excipients for use in the pharmaceutical compositions can be found in standard pharmaceutical texts, for example, Handbook of Pharmaceutical Excipients, 9thedition, Pharmaceutical Press, American Pharmaceutical Association, 2020.
[0414] The choice of the pharmaceutical carrier is dependent on the dosage form type, the dose, intended route of delivery, the physicochemical properties of the active compounds, and the required bioavailability and / or exposure profile. When used, the excipients of the pharmaceutical compositions should not adversely affect the stability, bioavailability, safety, and / or therapeutic efficacy of the active compounds, i.e. the MCIM compound used in the pharmaceutical compositions. Thus, the skilled person will appreciate that pharmaceutical compositions are provided wherein there is no significant incompatibility between any of the components of the dosage form.
[0415] It may be convenient or desirable to prepare, purify, and / or handle a corresponding solvate of the active compound(s). The term "solvate" is used herein in the conventional sense to refer to a complex of solute (e.g., active compound, salt of active compound) and solvent. If the solvent is water, the solvate may be conveniently referred to as a hydrate, for example, a mono-hydrate, a di-hydrate, a tri-hydrate, etc.
[0416] 008930943Unless otherwise specified, a reference to a particular compound also includes the solvate forms thereof. It may be convenient or desirable to prepare, purify, and / or handle a corresponding salt of the active compound(s), for example, a pharmaceutically-acceptable salt of an MCIM compound, for example HMC-C-01-A. Examples of pharmaceutically acceptable salts are discussed in Berge et al., 1977, " Pharmaceutically Acceptable Salts," J. Pharm. Sci., Vol. 66, pp. 1-19.
[0417] For example, if the compound is anionic, or has a functional group which may be anionic (e.g., COOH may be COO ), then a salt may be formed with a suitable cation. If the compound is cationic, or has a functional group which may be cationic (e.g., NH2 may be NH3+), then a salt may be formed with a suitable anion.
[0418] Patient
[0419] The term patient and subject are used herein interchangeably. The subject to be treated may be any animal or human. The subject is preferably mammalian, more preferably human. The subject may be a non-human mammal, but is more preferably human. The subject may be male or female. The subject may be a patient. Therapeutic uses may be in human or animals (veterinary use).
[0420] Methods of treatment
[0421] It is to be understood that where reference is made to an active compound for use in the treatment of a patient this also refers to a method of treating a patient, wherein the method comprises administering said active compound to the patient and vice versa. Likewise, it is to be understood that such references are to be considered as encompassing the manufacture of a medicament comprising the active compound for use in a method of treating a patient.
[0422] A treatment may involve administration of more than one MCIM compound. An MCIM compound may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated. For example, the MCIM compound may be a co-therapy involving administration of two drugs, compounds or pharmaceutical compositions, one or more of which may be intended to treat additional symptoms of causes of disease associated with muscle loss. The drugs, compounds or pharmaceutical compositions may be administered by one or more routes of administration, e.g. parenteral, intravenous injection, oral, subcutaneous, intradermal or intratumoral. Relatedly, in some embodiments, the MCIM compound may be administered in combination with a pharmaceutical composition comprising a muscle stem cell, myoblast, or myocyte. In some embodiments, the muscle stem cell is a quiescent satellite cell and / or an activated satellite cell. In some embodiments, the MCIM compound may be administered in combination with a pharmaceutical composition comprising a component of the satellite cell niche. In some embodiments, the muscle stem cell, or component of the satellite cell niche is from a donor subject not suffering from muscle loss. In some embodiments, the MCIM compound can be administered and / or used in combination with a pharmaceutical composition in the treatment of an autoimmune and / or neuromuscular condition. In some embodiments, the neuromuscular condition is muscular dystrophy and / or ALS.
[0423] 008930943In some embodiments, the MCIM compound is administered in combination with a treatment, treatment strategy, therapeutic, medicine and / or drug which induces, exacerbates, and / or is associated with muscle loss. In some embodiments, the MCIM compound is administered in combination with a treatment, treatment strategy, therapeutic, medicine and / or drug which induces, exacerbates, and / or is associated with sarcopenia and / or cachexia.
[0424] In some embodiments, the MCIM compound is administered in combination with an anti-diabetic drug which induces, exacerbates, and / or is associated with sarcopenia and / or cachexia. In some embodiments, the anti-diabetic drug is a glucagon-like peptide-1 receptor agonist (GLP-1 RA).
[0425] In some embodiments, the MCIM compound is administered in combination with a steroid which induces, exacerbates, and / or is associated with sarcopenia and / or cachexia. In some embodiments, the steroid is a corticosteroid or an anabolic-androgenic steroid. In some embodiments, the steroid is a glucocorticoid. In some embodiments, the steroid is an anabolic steroid or an androgen.
[0426] In some embodiments, the MCIM compound is administered in combination with an anti-cancer drug which induces, exacerbates, and / or is associated with sarcopenia and / or cachexia. In some embodiments, the MCIM compound is administered in combination with chemotherapy, immunotherapy, radiotherapy, surgery, vaccination and / or hormone therapy, which induces, exacerbates, and / or is associated with sarcopenia and / or cachexia.
[0427] The drugs, compounds or pharmaceutical compositions may be administered according to a treatment regime. The treatment regime may be a pre-determined timetable, plan, scheme or schedule of administration which may be prepared by a physician or medical practitioner and may be tailored to suit the patient requiring treatment and suffering from or at risk of muscle loss. The treatment regime may indicate one or more of: the type of drug, compound or pharmaceutical composition to administer to the patient; the dose of each drug, compound or pharmaceutical composition; the time interval between administrations; the length of each treatment; the number and nature of any treatment holidays, if any etc. For a co-therapy a single treatment regime may be provided which indicates how each drug, compound or pharmaceutical composition is to be administered.
[0428] Other definitions
[0429] For the purposes of this specification and appended claims, unless otherwise indicated, all numbers expressing quantities of ingredients, percentages or proportions of materials, reaction conditions, and other numerical values used in the specification and claims, are to be understood as being modified in all instances by the term “about” whether or not explicitly indicated. The term “about” generally refers to a range of numbers that one would consider equivalent to the recited value (i.e., having the same function or result). In many instances, the term “about” may include numbers that are rounded to the nearest significant figure.
[0430] 008930943Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
[0431] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements. Moreover, all ranges disclosed herein are to be understood to encompass all sub ranges subsumed therein. For example, a range of “1 to 10” includes any and all sub ranges between (and including) the minimum value of 1 and the maximum value of 10, that is, any and all sub ranges having a minimum value of equal to or greater than 1 and a maximum value of equal to or less than 10, e.g., 5.5 to 10.
[0432] ***
[0433] The features disclosed in the foregoing description, or in the following claims, or in the accompanying drawings, expressed in their specific forms or in terms of a means for performing the disclosed function, or a method or process for obtaining the disclosed results, as appropriate, may, separately, or in any combination of such features, be utilised for realising the invention in diverse forms thereof.
[0434] While the invention has been described in conjunction with the exemplary embodiments described above, many equivalent modifications and variations will be apparent to those skilled in the art when given this disclosure. Accordingly, the exemplary embodiments of the invention set forth above are considered to be illustrative and not limiting. Various changes to the described embodiments may be made without departing from the spirit and scope of the invention.
[0435] For the avoidance of any doubt, any theoretical explanations provided herein are provided for the purposes of improving the understanding of a reader. The inventors do not wish to be bound by any of these theoretical explanations.
[0436] Any section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0437] Throughout this specification, including the claims which follow, unless the context requires otherwise, the word “comprise” and “include”, and variations such as “comprises”, “comprising”, and “including” will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
[0438] It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Ranges may be expressed herein as from “about” one particular value, and / or to “about” another particular value. When such a range
[0439] 008930943is expressed, another embodiment includes from the one particular value and / or to the other particular value. Similarly, when values are expressed as approximations, by the use of the antecedent “about,” it will be understood that the particular value forms another embodiment. The term “about” in relation to a numerical value is optional and means for example + / - 10%.
[0440] 008930943Examples
[0441] EXAMPLE 1 - MCIM compound induced muscle repair in an RA model
[0442] The inventors considered whether MCIM compounds could be used to reverse the effects of muscle loss / wasting that develops as a result of several diseases such as cancer, HIV / AIDS, chronic obstructive pulmonary disease and rheumatoid arthritis. To evaluate the effects of MCIM on muscle loss, the inventors first utilised a collagen-induced arthritis model in mouse. This model effectively recapitulates clinical changes observed in rheumatoid arthritis (Alabarse etal., 2018) and more widely in secondary sarcopenia, as well as showing pathological features similar to those observed in primary sarcopenia. Seven- to eight-week-old male DBA / 1j mice were used for all procedures. Animals were housed in groups of 10 and were maintained at 21°C ± 2°C on a 12-hour light / dark cycle with food and water ad libitum. Complete Freund’s adjuvant (CFA) was prepared by emulsifying mouse type II collagen at 2 mg / mL with a 1 mg / mL suspension of Mycobacterium tuberculosis H37Ra in Incomplete Freund’s adjuvant (IFA) (0.85 mL paraffin oil and 0.15 mL mannide monooleate) in a 1:1 (v / v) ratio. All mice were immunised subcutaneously with 150 pl of mouse type II collagen in CFA. 21 days later, all mice were immunised subcutaneously with 150 pl of mouse type II collagen in IFA. 7 days later all animals were administered with 50 pg lipopolysaccharide. The mice started to develop signs and symptoms of arthritis following the ‘booster’ immunisation.
[0443] Animals were sorted into treatment groups with a minimum arthritic index of 2 and then dosed once daily for 15 days with test compound or vehicle by oral gavage, or twice daily by oral gavage for the known JAK kinase inhibitor upadacitinib, an approved RA treatment currently used in the clinic. On Day 15, animals were sacrificed, and whole limbs and two gastrocnemius and / or two soleus muscle samples were dissected and weighed. The left limb muscles were fixed in 10% neutral buffered formalin for 1 week prior to transfer to 70% ethanol. The right limb muscles were snap-frozen in isopentane over dry ice. The fixed limbs were processed into paraffin blocks and sectioned and then stained using Toluidine Blue.
[0444] For histopathological assessment of the biological effects of MCIM compounds in muscle samples from mice with rheumatoid arthritis, samples of gastrocnemius and / or soleus muscle were fixed in 10% neutral buffered formalin. The fixed limbs were processed into paraffin blocks and sectioned and then stained using haematoxylin and eosin.
[0445] Semi-quantitative grading of key histological parameters was performed using a five-point scale: 0 - no significant findings; 1 - minimal, usually focal lesions; 2 - moderate, focal; 3 - moderate, multi-focal or diffuse; 4 - marked. The following outcomes were assessed: myositis (inflammatory foci invading muscle block, usually in perimysium and endomysium); fibre degeneration and necrosis (often involving single fibre lesions); fat inclusions (fat droplets within fibre sheath); oedema (fluid inclusions within fibres or affecting perimysium zones); fibre atrophy (shrinkage of single fibres or fibre groups and expansion of endomysium zones); fibre hypertrophy (expansion of fibres or fibre blocks with shrinkage or loss of clear endomysium or perimysium zones).
[0446] 008930943Quantitative histopathology to assess fibre hypertrophy or atrophy was performed on matched transverse sections using planar morphometry. In brief, muscle blocks from naive mice were analysed by measuring the cross-sectional area (CSA) of 90-150 muscle fibres using GXCam image analysis software. The median CSA was calculated (in this study 1440 μM2) and the analysis repeated on vector and test groups to determine the percentage of fibres showing a CSA greater than the median CSA from naive mice. This distribution analysis lessens the impact of variable fixation, and therefore tissue shrinkage, that is commonly seen in muscle histology material.
[0447] The data were analysed by generating a mean score for each parameter in each treatment group. Test groups were compared to vehicle group by ANOVA using the Kruskal Wallis test statistic with exact P value comparisons. The data are shown in Figures 1 to 8. Data shown as mean ± standard error of the mean from all evaluations per animal per group. * p<0.05, ** p<0.01, *** p<0.005 vs vector. §§§ p<0.005 vs start of treatment (Figure 5). § p<0.05 §§§ p<0.005 vs Upadacitinib (Figure 7).
[0448] Imaging of cross-sections (Figure 1 A) and longitudinal sections (Figure 1 B) of muscle tissue from naive healthy mice revealed regularly sized myocytes and narrow layers of connective tissue (the endomysium and perimysium). Comparative sections were then prepared for muscle tissue from arthritic mice as shown in Figure 2A and Figure 2B. Mice with arthritis showed incidence of muscle fibre atrophy, as shown by a reduction in cross-sectional area of myocytes, (Figure 2A) not observed in naive mice (Figure 1 A). Moreover, muscle tissue from arthritic mice showed an increase in myositis within the muscle tissue as shown by the presence of inflammation infiltrates into the muscle tissue, particularly in the perimysium and endomysium (Figure 2B). Thus, the histological data demonstrate that the described methods can be followed to create a model for muscle loss / wasting.
[0449] The effect of MCIM compounds on muscle loss was then evaluated using MCIM compounds ABD900 and HMC-C-01-A. Administering ABD900 had a large effect on muscle tissue architecture, considerably increasing the cross-sectional area of muscle fibres compared to the vector control (Figure 3A and Figure 3B). The cross-sectional area of muscle fibres is a strong indication of muscle strength and is synonymous with overall muscle mass.
[0450] Quantification of several muscle degeneration parameters revealed both MCIM compounds reduced myositis (Figure 4A), fibre degradation (Figure 4B), fat inclusions (Figure 4C) and oedema (Figure 4D) within the muscle tissue compared to the vector control (ABD900 left panels, HMC-C-01-A right panels). Moreover, the MCIM compounds also had a considerable effect on muscle fibre architecture, with as little as 0.1 mg / kg significantly reducing muscle fibre atrophy (Figure 5A) and increasing muscle fibre hypertrophy (Figure 5B) and fibre cross sectional area (Figure 5C). Importantly treatment with HMC-C-01-A increased the % fibres with a CSA ≥1440 μM2significantly versus animals given vector during the study and animals evaluated prior to the start of dosing (V, DO) (Figure 5C, right panel). In addition, the % fibres with a CSA ≥1440 μM2in mice receiving HMC-C-01-A was not significantly different to that of naive, non-arthritic, (healthy) mice.
[0451] 008930943Surprisingly, the inventors also observed that administering the MCIM compound caused an expansion in the satellite cell niche of the muscle, as shown by the proliferation and clustering of satellite cell nuclei and absence of significant inflammation (Figure 6). Proliferation of activated satellite cells is one of the first steps in muscle tissue repair and regeneration and is unexpected given MCIM compounds are known to attenuate proliferation of other cell types.
[0452] The efficacy of an MCIM compound to treat muscle loss was next compared to upadacitinib. While the reduction in myositis resulting from ABD900 treatment was comparable to upadacitinib, the MCIM greatly outperformed upadacitinib at inducing muscle fibre hypertrophy (Figure 7), resulting in a greater proportion of muscle fibres with a cross-sectional area greater than 1440 μM2. Remarkably, ABD900 completely inhibited muscle fibre atrophy (Figure 7) while upadacitinib could only reduce atrophy by approximately half (Figure 7). This difference is most likely due to the combined impact of ABD900 on both inflammation (myositis) and fibre hypertrophy, the latter not being seen with upadacitinib.
[0453] T o evaluate the effect of changing muscle fibre architecture at the organism level, total gastrocnemius and soleus muscle mass following treatment with MCIM compounds HMC-C-01-A and ABD900 was evaluated. MCIM compounds were shown to increase total soleus muscle weight (Figure 8A) and the relative amount of both the gastrocnemius and soleus muscle as a proportion of total body weight (Figure 8B). These results demonstrate that administration of MCIM compounds can increase muscle mass. Together, these data demonstrate that MCIM compounds are not only able to reduce myositis and muscle atrophy, but actively promote muscle fibre hypertrophy, resulting in muscle fibres with greater cross-sectional area. This contrasts with the approved RA drug upadacitinib which is unable to promote muscle repair / regeneration in RA and had limited impact on muscle atrophy, despite strong antiinflammatory effects on myositis.
[0454] EXAMPLE 2 - MCIM compound induced muscle repair in an IBD model
[0455] Sarcopenia is prevalent in patients suffering with IBD, and offers a second setting for the evaluation of secondary sarcopenia, as well as modelling the pathology of primary sarcopenia. Accordingly, the inventors next looked to evaluate the effect of MCIM compounds on muscle loss in a mice IBD model. DSS-induced colitis is a widely used model of IBD (Chassaing et al, 2015, which is hereby incorporated by reference in its entirety). Eight- to nine-week-old female C57BI / 6 mice were used for all procedures. Animals were housed in groups of 10 and were maintained at 21 °C ± 2°C on a 12-hour light / dark cycle with food and water ad libitum. Dextran sulphate (DSS) was prepared by dissolving DSS in water to a final concentration of 1.5%. All mice were given ad libitum access to the DSS-containing water for 6 hours prior to dosing with vehicle control, or MCIM test compound at 1, 3 or 10 mg / kg by oral gavage, once daily for 8 days. The mice started to develop signs and symptoms of colitis within 1 day.
[0456] 008930943On Day 8, animals were sacrificed, and muscle samples were dissected and weighed. Samples of gastrocnemius muscle were fixed in 10% neutral buffered formalin. The fixed limbs were processed into paraffin blocks and sectioned and then stained using Toluidine Blue.
[0457] For histopathological assessment of the biological effects of MCIM compounds in muscle samples from mice with DSS-induced colitis, semi-quantitative grading of key histological parameters was performed using a five-point scale: 0 - no significant findings; 1 - minimal, usually focal lesions; 2 - moderate, focal; 3 - moderate, multi-focal or diffuse; 4 - marked. The following outcomes were assessed; fibre atrophy (shrinkage of single fibres or fibre groups and expansion of endomysium zones) and fibre hypertrophy (expansion of fibres or fibre blocks with shrinkage or loss of clear endomysium or perimysium zones). The data were analysed by generating a mean score for each parameter in each treatment group. Test groups were compared to vector group by ANOVA using the Kruskal Wallis test statistic with exact P value comparisons. Data shown in the relevant figures are a sum from all limbs per animal per group. * p<0.05, ** p<0.01, *** p<0.005 vs vector.
[0458] Treatment with the MCIM compound ABD900 reduced muscle fibre atrophy but also increased muscle fibre hypertrophy in mice with DSS-induced colitis (Figure 9), confirming the results obtained in the collagen induced arthritis model. These data demonstrate that MCIM compounds can be used to treat secondary sarcopenia and to positively benefit muscle pathology (fibre atrophy and reduced hypertrophy) observed in primary sarcopenia.
[0459] EXAMPLE 3 - MCIM compound induced reduction of sarcopenia in patients with rheumatoid arthritis Sarcopenia is prevalent in patients suffering with RA. Accordingly, the inventors next looked to evaluate the effect of MCIM compounds on muscle loss in patients with severe RA receiving treatment with MCIM compound, HMC-C-01A.
[0460] 248 patients with moderate to severe active RA, who had not responded to treatment with methotrexate for at least three months, were enrolled on the trial and randomly assigned to receive 1 of 3 doses of HMC-C-01-A (5 mg, 20 mg, or 40 mg) or placebo (a “dummy” drug). Following screening, patients were treated for a period of 12 weeks, and a follow-up period of 6 weeks. Patients received HMC-C-01-A once daily and methotrexate once weekly during the treatment period.
[0461] To investigate the effect of the MCIM compound on muscle loss in patients, the concentrations of three biomarkers were assessed in plasma samples taken at baseline (at the start of treatment) and week 12 of treatment. Growth Differentiation Factor 15 (GDF15) is a marker of integrated stress which is an emerging biomarker of skeletal muscle dysfunction in conditions like sarcopenia, muscle wasting and ageing (Chiariello et al., 2024 and Chen et al., 2025). C-terminal agrin fragment (CAF) is a product of neurotrypsin mediated cleavage of agrin and is a biomarker of sarcopenia and muscle wasting in ageing and disease (Monti etal., 2023). Fibroblast Growth Factor 21 (FGF-21) is peptide hormone which regulates several metabolic processes including energy expenditure, metabolic adaptation and the regulation of muscle mass (Tezze et al., 2019).
[0462] 008930943Analysing these biomarkers showed that treatment with HMC-C-01-A significantly reduces circulating GDF15 levels (Figure 10A) and increases FGF-21 levels (Figure 10B) compared with placebo, showing that MCIM compounds can elicit metabolic adaptation to reduce skeletal muscle dysfunction, and the symptoms of ageing. Moreover, CAF levels were also reduced following MCIM compound treatment (Figure 10C), demonstrating that MCIM compounds reduce sarcopenia and muscle wasting in humans. During the treatment and follow-up periods, patients attended a hospital or clinic for regular visits during which they underwent planned study assessments to evaluate the effectiveness, tolerability and safety of HMC-C-01-A including patient functional assessment using the HAQ-DI method (Wolfe 1994, Bruce and Fries 2003).
[0463] The HAQ-DI method includes questions related to whether a patient has difficulty in performing a range of everyday activities, the answer to which are indicative of the level of functional disability experienced by a patient. While this methodology can be used to assess functional disability specifically in RA patients, the scoring method can also be used to measure functional disability in other patient groups, such as patients with age-related functional decline / disability. Baseline values were acquired for each patient prior to commencement of treatment with HMC-C-01-A and then assessed again at week 12 of treatment.
[0464] The questions in the HAQ-DI questionnaire include the following:
[0465] Are you able to shampoo your hair? Are you able to stand up from a chair? Are you able to get in and out of bed? Are you able to cut your meat? Are you able to lift a full cup or glass to your mouth? Are you able to walk outdoors on flat ground? Are you able to climb up five steps? Are you able to take a tub bath? Are you able to reach and get down a 5 pound object (such as a bag of sugar) from just above your head? Are you able to bend down to pick up clothing from the floor? Are you able to open car doors? Are you able to do chores such as vacuuming or yard work?
[0466] Analysing these individual disability components of the HAQ-DI reveals that treatment with HMC-C-01-A significantly improves key measures for indicating an improvement in patient quality of life. Figure 11 shows that (in the full study analysis set), following a 12-week course of treatment with HMC-C-01-A (pooled for all doses), an increase in patients reporting no problems with arising from bed, walking or climbing stairs, using the toilet, reaching down or opening car doors. T ogether these data clearly show that following treatment with HMC-C-01-A, a significant proportion of patients experience a reversal in functional decline which taken together clearly indicate an increase in quality-of-life. In addition, the improvements are concentrated in functions requiring muscular engagement, such as walking and arising, whilst tendon oriented functions such as opening faucets to eat are unaffected, indicating beneficial effects on muscle function following treatment.
[0467] EXAMPLE 4 - MCIM compound induced muscle repair in aged mice
[0468] The inventors considered whether MCIM compounds could be used to reverse the effects of muscle loss / wasting that develops as a result of aging. To evaluate the effects of MCIM on muscle loss, the inventors utilised mice of an advanced age; 23 months. This model effectively recapitulates clinical
[0469] 008930943changes observed in human aging (Alabarse et al., 2018) including pathological features similar to those observed in primary sarcopenia, as well as similarities to the pathology observed in secondary sarcopenia.
[0470] 23-month-old male C57BI6 / j mice were used for all procedures. Animals were singly housed and were maintained at 21 °C ± 2°C on a 12-hour light / dark cycle with food and water ad libitum. Owing to the age of the animals, from Day 42 onwards the diet was supplemented with a food jelly.
[0471] Animals were sorted into treatment groups of 12 at baseline based on food-intake, body weight, body composition, grip strength and endurance testing and then dosed once daily for 84 days with test compound, or vehicle, by oral gavage. On Day 84, when mice were between 25 and 26 months of age, animals were sacrificed, and two gastrocnemius samples were dissected.
[0472] For histopathological assessment of the biological effects of MCIM compounds in muscle samples from aged mice, samples of right gastrocnemius muscle were fixed in 10% neutral buffered formalin. The fixed limbs were processed into paraffin blocks and sectioned and then stained using haematoxylin and eosin and Martius Scarlet Blue. Haematoxylin and eosin-stained sections were used to assess myositis; degeneration / necrosis; fat inclusions; oedema; satellite cell expansion and cross-section area morphometry of fibres. Martius Scarlet Blue sections were used to delineate the morphology of the endomysium and perimysium to contextualise the Satellite cell assessment.
[0473] Semi-quantitative grading of key histological parameters was performed using a five-point scale: 0 - no significant findings; 1 - minimal, usually focal changes; 2 - moderate, focal; 3 - moderate, multi-focal or diffuse; 4 - marked. The following outcomes were assessed: fibre degeneration and necrosis (often involving single fibre lesions); fat inclusions (fat droplets within fibre sheath); oedema (fluid inclusions within fibres); satellite cell expansion (increased satellite cell foci in myofibre cross-sections and increased satellite cell forms in endomysium and perimysium).
[0474] Quantitative histopathology to assess fibre hypertrophy or atrophy was performed on matched transverse sections using planar morphometry. In brief, muscle blocks from naive mice were analysed by measuring the cross-sectional area (CSA) of 90-150 muscle fibres using GXCam captured images and analysed using the QuPath linear measurement tool analysis software. The median CSA was calculated (in this study 1360 μM2) and the analysis repeated on vehicle and test groups to determine the percentage of fibres showing a CSA greater than the median CSA from animals given vehicle. This distribution analysis lessens the impact of variable fixation, and therefore tissue shrinkage, that is commonly seen in muscle histology material.
[0475] Immunohistochemistry of the proliferation marker Ki67 was used to assess active or recent proliferative portion of the satellite cell population. For determination of the muscle isoform phenotype, muscle sections were stained for myosin heavy chain 1 (Type llx / d, fast twitch) using an anti-MYH1 antibody and myosin heavy chain 7 (slow twitch) using an anti-MHC7 antibody. The total number of cross-section fibres was counted and MYH1 and MHC7 positive fibres expressed as a percentage, normalised for 100 fibres. Intermediate fibre forms were not assessed.
[0476] 008930943The data were analysed by generating a mean score for each parameter in each treatment group. Test groups were compared to the baseline group or the vehicle group by ordinary one-way ANOVA using the Fisher’s least squares difference test with exact P value comparisons. The data are shown in Figures 12 to 14. Data shown as mean ± standard error of the mean from all evaluations per animal per group. * p<0.05, ** p<0.01, *** p<0.005 vs vector. § p<0.05 §§ p<0.01 §§§ p<0.005 vs start of treatment (Figures 12 to 14).
[0477] The effect of MCIM compounds on muscle loss was evaluated using MCIM compound HMC-C-01-A. Quantification of several muscle degeneration parameters revealed that mice given vehicle for 84 days showed significant increases in fibre degradation (Figure 12A), fat inclusions (Figure 12B) and oedema (Figure 12C) compared with baseline (BL) values in 23-month old mice, confirming degenerative changes in the muscle with age. In addition, the MCIM compound reduced fibre degradation (Figure 12A), fat inclusions (Figure 12B) and oedema (Figure 12C) within the muscle tissue compared to vehicle control. Furthermore, the effect of the MCIM on oedema was of such a magnitude that oedema was significantly reduced compared with baseline animals at 23 months of age. The MCIM compound also had a considerable effect on muscle fibre architecture. Whilst vehicle treated mice showed a decrease in fibre cross-sectional area compared with baseline indicating a degenerative change, a dose of 3 mg / kg or 10 mg / kg of MCIM compound significantly increased muscle fibre hypertrophy compared with vehicle as indicated by an increase in fibre cross sectional area (Figure 13A), and a dose of 10 mg / kg of MCIM compound significantly increasing fibre cross-sectional area compared with baseline. To further understand the mechanism by which these changes occurred the inventors evaluated the effects of MCIM compound on satellite cells.
[0478] Surprisingly, the inventors observed that the MCIM compound had a considerable effect on the number of satellite cells (Figure 14A), and in particular an increase in the percentage of Ki67+ve satellite cells (Figure 14B). Administering the MCIM compound caused an expansion in satellite cell niche of the muscle, as shown in Figure 14A and B (satellite cell number and % positive for the marker Ki67, respectively). Proliferation of activated satellite cells is one of the first steps in muscle tissue repair and regeneration and is unexpected given MCIM compounds are known to attenuate proliferation of other cell types. The expansion in the muscle stem cell niche is also coupled with an increase in muscle cells. The percentage of myosin heavy chain 7 (MHC7) positive cells (Type I muscle fibres) was also significantly increased in all treatment groups compared to baseline and vehicle control (Figure 15A). Finally, MHC1 positive (type 2 muscle fibres) was also seen to increase from baseline in mice treated with 3 mg / kg and 10 mg / kg MCIM compound (Figure 15B).
[0479] These data demonstrate that MCIM compounds have two surprising effects on muscle loss / wasting that develops as a result of aging. Firstly, the data shows that MCIM compounds reduce muscle atrophy associated with aging. In addition, MCIM compounds surprisingly actively promote muscle fibre hypertrophy, resulting in muscle fibres with greater cross-sectional area. Together, this data provides promising results for the treatment and reversal of age-related muscle wasting.
[0480] 008930943Grip strength
[0481] To test whether the increase in muscle mass seen in mice treated with MCIM compounds also led to an increase in muscle function, the inventors next performed a series of grip strength tests. The grip strength test (Ferraro et al., J Cachexia Sarcopenia Muscle. 2016; Bonetto et al., Bonekey Rep. 2015; Capers et al., J Nutr Sci. 2015) was used to measure the maximal muscle strength of the forelimbs using a bar, or of the combined forelimbs and hindlimbs using a grid assembly connected to a grip strength meter.
[0482] Grip strength was assessed at baseline prior to dosing and then again following 42 days and 84 days of administration of vector or MCM compound.
[0483] For forelimb strength measurement, the mouse was placed slowly over the bar assembly connected to a grip strength meter so that only its front paws can grip the bar. The torso was kept horizontal and the mouse pulled back steadily until the grip was released down the complete length of the grid. When the animal released its grip, the maximal grip strength value was displayed on the screen of the device (Test Sensor and Display unit Model BIO-GS3; BIOSEB, France) and automatically recorded by an acquisition software (BIO-CIS; BIOSEB, France). The procedure was repeated 3 times with 5 minutes intervals between measurements to obtain 3 independent measurements per animal per time point. The bar was cleaned with 50% ethanol and dried between each animal.
[0484] For combined forelimb and hindlimb strength measurement, the mouse was placed slowly over the top of the grid so that both its front paws and hind paws could grip the grid. The torso was kept parallel to the grid and the mouse pulled back steadily until the grip was released down the complete length of the grid. When the animal released its grip, the maximal grip strength value was displayed on the screen of the device (Test Sensor and Display unit Model BIO-GS3; BIOSEB, France) and automatically recorded by an acquisition software (BIO-CIS; BIOSEB, France). The procedure was repeated 3 times with 5-minute intervals between measurements to obtain 3 independent measurements per animal per time point. The grid was cleaned with 50% ethanol and dried between each animal.
[0485] Grip strength at each time point was calculated as the mean of the 3 repeated measurements in each animal.
[0486] The data were analysed by generating a mean across each group at baseline and for subsequent time points, by subtracting the baseline measurement from each Day 42 (Figures 16A and 16B) or Day 84 (Figures 16C and 16D) measurement for each animal and generating a mean score for change from baseline for each parameter in each treatment group. One animal given 3 mg / kg / day MCIM was excluded from analysis due to its condition. Test groups were compared to vehicle group by ordinary one-way ANOVA using the Fisher’s least squares difference test with exact P value comparisons. Data shown as mean ± standard error of the mean from all evaluations per animal per group. * p<0.05, ** p<0.01, *** p<0.005 vs vehicle. § p<0.05 §§ p<0.01 §§§ p<0.005 vs start of treatment (Figure 16).
[0487] 008930943The effect of MCIM compounds on grip strength was evaluated using MCIM compound HMC-C-01-A. Table 1 shows that the baseline grip strength values were similar across treatment groups:
[0488]
[0489] The MCIM compound improved forelimb, and combined forelimb and hindlimb grip strength (Figure 16) compared to the vehicle control. Moreover, the MCIM compound also had a considerable effect on grip strength compared with baseline. Whilst forelimb grip strength showed no significant change compared with baseline in animals given vehicle, mice treated with the MCIM compound showed a significant increase in forelimb grip strength compared with baseline at both Day 42 (Figure 16A) and Day 84 (Figure 16C). In addition, looking at combined forelimb and hindlimb grip strength, animals given vehicle showed no significant change compared with baseline on Day 42 (Figure 16B) but a significant decrease on Day 84 (Figure 16D). By contrast, animals treated with MCIM showed significant increases in combined FL and HL grip strength compared with baseline, in addition to significant increases compared with time-matched vehicle
[0490] The findings are of note because the improvement in grip strength compared with both vehicle and baseline indicates that treatment elicits restoration of, and improvement in, muscle functional parameters, rather than reduced rate of decline. Combined with the striking improvements in satellite cell numbers compared with both vector and baseline this suggests the potential for MClMs to elicit muscle repair and regeneration.
[0491] References
[0492] A number of publications are cited above in order to more fully describe and disclose the invention and the state of the art to which the invention pertains. Full citations for these references are provided below. The entirety of each of these references is incorporated herein.
[0493] Alabarse PVG, Lora PS, Silva JMS, et al. Collagen-induced arthritis as an animal model of rheumatoid cachexia. J Cachexia Sarcopenia Muscle. 2018;9(3):603-612
[0494] Ali S, Garcia JM. Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options - a mini-review. Gerontology. 2014;60(4):294-305.
[0495] 008930943Argiles JM, Lopez-Soriano FJ, Toledo M, Betancourt A, Serpe R, Busquets S. The cachexia score (CASCO): a new tool for staging cachectic cancer patients. J Cachexia Sarcopenia Muscle. 2011 Jun;2(2):87-93.
[0496] Argiles JM, Busquets S, Stemmier B, Lopez-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014; 14( 11): 754-762.
[0497] Bennett JL, Pratt AG, Dodds R, Sayer AA, Isaacs JD. Rheumatoid sarcopenia: loss of skeletal muscle strength and mass in rheumatoid arthritis. Nat Rev Rheumatol. 2023;19(4):239-251.
[0498] Berge et al., 1977, " Pharmaceutically Acceptable Salts," J. Pharm. Sci., Vol. 66, pp. 1-19
[0499] Bermejo I, Carnicero JA, Garcia FJ on behalf of Bone and Joint Research Unit, et al POS1446 CREATINE KINASE COULD BE A MARKER OF CHRONIC INFLAMMATION-INDUCED SARCOPENIA IN FRAIL PATIENTS. Annals of the Rheumatic Diseases 2022;81:1067-1068.
[0500] Biressi S, Filareto A, Rando TA. Stem cell therapy for muscular dystrophies. J Clin Invest.
[0501] 2020; 130(11): 5652-5664.
[0502] Bodine SC, Furlow JD. Glucocorticoids and Skeletal Muscle. Adv Exp Med Biol. 2015;872:145-176. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qua! Life Outcomes. 2003; 1:20
[0503] Campelj DG, Goodman CA, Rybalka E. Chemotherapy-Induced Myopathy: The Dark Side of the Cachexia Sphere. Cancers. 2021; 13(14):3615.
[0504] Calvez V, Becherucci G, Covello C, Piccirilli G, Mignini I, Esposto G, Laterza L, Ainora ME, Scaldaferri F, Gasbarrini A, et al. Navigating the Intersection: Sarcopenia and Sarcopenic Obesity in Inflammatory Bowel Disease. Biomedicines. 2024; 12(6): 1218
[0505] Chassaing B, Koren O, Goodrich JK, et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome [published correction appears in Nature. 2016 Aug 11;536(7615):238. doi: 10.1038 / nature18000.]. Nature. 2015;519(7541 ):92-96.
[0506] Chen J, Kastroll J, Bello FM, et al. Skeletal muscle mitochondrial dysfunction is associated with increased Gdf15 expression and circulating GDF15 levels in aged mice. Sci Rep. 2025; 15(1 ):8101.
[0507] Chiariello A, Conte G, Rossetti L, Trofarello L, Salvioli S, Conte M. Different roles of circulating and intramuscular GDF15 as markers of skeletal muscle health. Front Endocrinol (Lausanne). 2024; 15: 1404047.
[0508] Dalle S, Rossmeislova L, Koppo K. The Role of Inflammation in Age-Related Sarcopenia. Front Physiol.
[0509] 2017;8: 1045.
[0510] De Paepe B. The Cytokine Growth Differentiation Factor-15 and Skeletal Muscle Health: Portrait of an Emerging Widely Applicable Disease Biomarker. Int J Mol Sci. 2022;23(21):13180
[0511] Dhaliwal A, Quinlan JI, Overthrow K, et al. Sarcopenia in Inflammatory Bowel Disease: A Narrative Overview. Nutrients. 2021;13(2):656.
[0512] Evans WJ. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Am J Clin Nutr. 2010;91 (4):1123S-1127S
[0513] Fatima R, Kim Y, Baek S, Suram RP, An SL, Hong Y. C-Terminal Agrin Fragment as a Biomarker for Sarcopenia: A Systematic Review and Meta-Analysis. J Cachexia Sarcopenia Muscle. 2025;16(1):e1370 Fenton CG, Webster JM, Martin CS, et al. Therapeutic glucocorticoids prevent bone loss but drive muscle wasting when administered in chronic polyarthritis. Arthritis Res Then 2019;21 (1 ): 182.
[0514] Ferrer M, Anthony TG, Ayres JS, et al. Cachexia: A systemic consequence of progressive, unresolved disease. Cell. 2023; 186(9): 1824-1845
[0515] Ji et al., Antioxidants 2020 11(9), 1686).
[0516] Jia P-W, Lin J-Z, Zou Y-W, Ouyang Z-M, Yang Y, Yang K-M, Liang L-H, Han J-Y, Yang Z-H, Ma J-D, et al. The Characteristic of Muscle Function for Sarcopenia in Patients with Rheumatoid Arthritis: A Large-Scale Real-World Cross-Sectional Study. Medicina. 2025; 61(4):551.
[0517] Lee SH, Gong HS. Measurement and Interpretation of Handgrip Strength for Research on Sarcopenia and Osteoporosis. J Bone Metab. 2020 May;27(2):85-96. doi: 10.11005 / jbm.2020.27.2.85. Epub 2020 May 31. PMID: 32572369; PMCID: PMC7297622.
[0518] Lee MK, Jeong HH, Kim MJ, Ryu H, Baek J, Lee B. Nutrients against Glucocorticoid-Induced Muscle Atrophy. Foods. 2022;11(5):687.
[0519] Leone A, Carluccio AM, Caroppo A, Manni A, Rescio G. A Systematic Review of Surface Electromyography in Sarcopenia: Muscles Involved, Signal Processing Techniques, Significant Features, and Artificial Intelligence Approaches. Sensors (Basel). 2025;25(7):2122
[0520] Liu H, Huang Y, Lyu Y, Dai W, Tong Y, Li Y. GDF15 as a biomarker of ageing. Exp Gerontol.
[0521] 2021; 146:111228.
[0522] Mackenzie et al., Seminars in pediatric neurology (2021), 37, 100877
[0523] Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc. 2013 Aug;14(8):531-2
[0524] 008930943Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016 Mar;7(1):28-36.
[0525] Monti E, Sarto F, Sartori R, et al. C-terminal agrin fragment as a biomarker of muscle wasting and weakness: a narrative review. J Cachexia Sarcopenia Muscle. 2023; 14(2)730-744.
[0526] Moschou D, Krikelis M, Georgakopoulos C, et al. Sarcopenia in Rheumatoid arthritis. A narrative review. J Frailty Sarcopenia Falls. 2023;8(1):44-52
[0527] Nardone OM, de Sire R, Petito V, et al. Inflammatory Bowel Diseases and Sarcopenia: The Role of Inflammation and Gut Microbiota in the Development of Muscle Failure. Front Immunol. 2021;12:694217. Ochi S, Sonomoto K, Tanaka Y. Residual symptoms: Unmet needs for rheumatoid arthritis patients who achieved low clinical disease activity. Curr Rheumatol Res. 2024;4(1): 19-27.
[0528] Ollewagen T, Myburgh KH, van de Vyver M, Smith C. Rheumatoid cachexia: the underappreciated role of myoblast, macrophage and fibroblast interplay in the skeletal muscle niche. J Biomed Sci. 2021;28(1):15 Ottery, F., Physical Examination from a Nutritional Standpoint, https: / / pt-global.org / wp-content / uploads / 2014 / 12 / Physical_Examination_from_a_Nutritional_Standpoint_Ottery-FD-2001.pdf (accessed 22 April 2025)
[0529] Pereira RM, Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine. 2011;78(1 ):41-44. Pratt J, Motanova E, Pessanha L, Narici M, Boreham C, De Vito G. Plasma C-terminal agrin fragment concentrations across adulthood: Reference values and associations with skeletal muscle health. J Cachexia Sarcopenia Muscle. 2024; 15(4): 1501 -1510.
[0530] Scaricamazza S, Salvatori I, Ferri A, Valle C. Skeletal Muscle in ALS: An Unappreciated Therapeutic Opportunity?. Cells. 2021;10(3):525
[0531] Setiawan T, Sari IN, Wijaya YT, et al. Cancer cachexia: molecular mechanisms and treatment strategies. J Hematol Oncol. 2023;16(1):54.
[0532] Sousa-Victor et al., Molecular cell biology (2022) 23(3), 204–226
[0533] Tezze C, Romanello V, Sandri M. FGF21 as Modulator of Metabolism in Health and Disease. Front Physiol. 2019; 10:419.
[0534] Torii M, Itaya T, Minamino H, et al. Management of sarcopenia in patients with rheumatoid arthritis. Mod Rheumatol. 2023;33(3):435-440
[0535] Vaes et al. Intestinal smooth muscle aberrations in pancreatic cancer patients with sarcopenia. JCSM Comms. 2021; 4(2): 187-196.
[0536] Walston JD. Sarcopenia in older adults. Curr Opin Rheumatol. 2012;24(6):623-627
[0537] Wolfe F, Pincus T, Dekker M, eds. Rheumatoid arthritis: pathogenesis, assessment, outcome and treatment. New York: Marcel Dekker, 1994: 463-514
[0538] Zhang, Journal of cachexia, sarcopenia and muscle (2021) 12(6), 1368–1379
[0539] 008930943
Claims
Claims1. A mitochondrial complex 1 modulator (MCI M) compound for use in the treatment or prevention of muscle loss in a subject, wherein the treatment comprises administering to the subject a compound, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, according to a formula selected from:
2. The compound for use according to claim 1, wherein the muscle loss is:i) sarcopenia, optionally primary sarcopenia or secondary sarcopenia;ii) cachexia, optionally cachexia associated with disease, or drug-induced cachexia;iii) muscular atrophy associated with inactivity; and / oriv) muscle loss associated with a neuromuscular disorder.
3. The compound for use according to claim 2, wherein the secondary sarcopenia is induced by, exacerbated by, or associated with an autoimmune disease, a fibrotic disease and / or a neurological disease.
4. The compound for use according to claim 3, wherein the autoimmune disease is rheumatoid arthritis or inflammatory bowel disease ( IBD).
5. The compound for use according to any one of claim 2 to claim 4, wherein the secondary sarcopenia is osteosarcopenia.
6. The compound for use according to any one of claim 2 to claim 4, wherein the secondary sarcopenia is sarcopenic obesity.
7. The compound for use according to any of claim 2 to claim 6, wherein the secondary sarcopenia is induced by, exacerbated by, or associated with metabolic dysfunction-associated steatohepatitis (MASH) and / or metabolic dysfunction-associated steatotic liver disease (MASLD).
8. The compound for use according to any one of claim 2 to claim 7, wherein the secondary sarcopenia is induced by, exacerbated by and / or associated with a treatment, treatment strategy, therapeutic, medicine and / or drug.
9. The compound for use according to claim 8, wherein the treatment, treatment strategy, therapeutic, medicine and / or drug is for the treatment of diabetes, cancer, an autoinflammatory condition, an autoimmune condition and / or a neuromuscular condition.
10. The compound for use according to claim 8 or claim 9, wherein the drug is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or a steroid.
11. The compound for use according to claim 2, wherein the neuromuscular disorder is muscular dystrophy or ALS.
12. The compound for use according to claim 2, wherein the cachexia is associated with cancer, pancreatic cancer, stomach cancer, oesophageal cancer, colorectal cancer, chronic obstructive pulmonary disease (COPD), heart failure, chronic kidney disease, HIV / AIDS, sepsis, Emphysema, organ failure, Alzheimer’s disease, dementia, congestive heart failure (CHF), chronic kidney disease cystic fibrosis, arthritis, rheumatoid arthritis, Crohn's disease, tuberculosis, colitis, MASH, MASLD or any disease with associated muscle loss.
13. The compound for use according to any of the preceding claims, wherein the subject to be treated is identified as having;a HAQ-DI score of 1-3;a SARC-F score of 4 or more;a CASCO classification of mild, moderate, severe or terminal;a visual reduction in muscle mass and / or symmetry indicative of muscle wasting and / or atrophy; and / ora BMI over 30.
14. The compound for use according to any one of the preceding claims, wherein administration of the compound to the subject reduces the HAQ-DI score, the SARC-F score, the CASCO score, or visual signs of muscle loss in a subject.
15. The compound for use according to any one of the preceding claims, wherein administration of the compound to the subject:(i) increases muscle mass of the subject compared to the muscle mass of the subject prior to commencing treatment with the compound;(ii) maintains muscle mass of the subject compared to the muscle mass of the subject prior to commencing treatment with the compound, wherein the subject has a muscle wasting disease or disorder according to claims 2 to 12; and / or(iii) reduces the rate of loss of muscle mass in a subject compared to the rate of loss of muscle mass in the subject prior to commencing treatment with the compound.
16. The compound for use according to any one of the preceding claims, wherein administration of the compound to the subject:(i) increases muscle hypertrophy and / or the cross-sectional area of muscle fibres of the subject compared to the subject prior to commencing treatment with the compound; and / or (ii) maintains muscle hypertrophy and / or the cross-sectional area of muscle fibres of the subject compared to the subject prior to commencing treatment with the compound.
17. The compound for use according to any one of the preceding claims, wherein administration of the compound to the subject:(i) reduces muscle fibre atrophy, myositis, fibre degeneration, oedema, fat inclusion size and / or fat inclusion number in muscle tissue, or any combination thereof, compared to the subject prior to commencing treatment with the compound; and / or,(ii) inhibits muscle fibre atrophy, myositis, fibre degeneration, oedema, development of fat inclusions in muscle tissue, or any combination thereof, compared to the subject prior to commencing treatment with the compound.
18. The compound for use according to any one of claims 15 to 17, wherein muscle mass, muscle hypertrophy, muscle fibre atrophy, myositis, fibre degeneration, oedema, fat inclusion size and / or fat inclusion number is measured using ultrasonography, magnetic resonance imaging (MRI), computed tomograph (CT), ultrasonography (US), dual-energy X-ray absorptiometry (DXA), bioelectrical impedance analysis (BIA), skinfold thickness measurements (SFT), and / or air displacement plethysmography (ADP), or any combination thereof; optionally wherein measurements are taken before, during and / or after administration of the compound to the subject.
19. The compound for use according to any of the preceding claims, wherein administering the compound reduces the amount of a biomarker that positively correlates with muscle loss in a subject relative to the same subject prior to administering the MCIM compound.
20. The compound for use according to any of the preceding claims, wherein administering the MCIM compound increases the amount of a biomarker that positively correlates with muscle regeneration and / or hypertrophy in a subject relative to the same subject prior to administering the MCIM compound.
21. The compound for use according to claim 19 or 20, wherein the biomarker is a muscle protein or a fragment thereof, a transcription factor, and / or a cytokine.
22. The compound for use according to claim 19 or 21, wherein the biomarker is C-terminal agrin fragment (CAF), growth differentiation factor-15 (GDF15), C-reactive protein (CRP) and / or creatine kinase.
23. The compound for use according claim 20 or 21, wherein the biomarker is fibroblast growth factor-21 (FGF-21), PI3K, mTORC1, mTORC2, FOXO, MyoD, and / or myogenin.
24. The compound for use according to any of the preceding claims, wherein administering the MCIM compound reduces the HAQ-DI score of a subject.
25. The compound for use according to any of the preceding claims, wherein the compound prevents satellite cells from reaching a disease like state, optionally wherein the compound prevents loss of muscle regeneration potential of satellite cells and / or prevents loss of the number of satellite cells compared to prior to the onset of disease or inactivity.
26. The compound for use according to any of the preceding claims, wherein the compound stimulates expansion of a satellite cell niche microenvironment.
27. The compound for use according to any of the preceding claims wherein the compound stimulates activation of quiescent satellite cells to generate activated satellite cells.
28. The compound for use according to claim 27, wherein the compound stimulates proliferation of the activated satellite cells.
29. The compound for use according to claim 27 or claim 28, wherein the compound stimulates differentiation of activated satellite cells to myocytes.
30. The compound for use according claim 29, wherein the compound stimulates differentiation of myocytes to myotubes.
31. The compound for use according to any of the preceding claims, wherein the muscle is skeletal muscle and / or smooth muscle.
32. A non-therapeutic method of slowing the progression of primary sarcopenia comprising administering to the subject a compound, or a salt, hydrate, or solvate thereof, according to a formula selected from:of W02020 / 035560 A1 and33. A non-therapeutic method of promoting muscle growth and / or inhibiting muscle loss in a subject comprising administering to the subject a compound, or a salt, hydrate, or solvate thereof, according to a formula selected from:
34. The method according to claim 32 or 33 wherein the primary sarcopenia, muscle growth, or muscle loss is determined by measuring a biomarker that correlates with ageing.
35. The method according to claim 34, wherein the biomarker is indicative of chronic systemic inflammation.
36. The method according to claim 35, wherein the biomarker is GDF15.
37. The method according to claim 34, wherein the biomarker is FGF21.
38. The compound for use, or the method, according to any one of the preceding claims, wherein the compound is a compound selected from compounds of the following formulae, or a pharmaceutically acceptable salt, hydrate, or solvate thereof:or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
39. The compound for use, or the method, according to any one of the preceding claims, wherein the MCIM compound is selected from compounds of the following formulae:or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
40. The compound for use, or the method, according to any one of claims 1 to 38, wherein the MCIM compound is a compound of the following formula, or a pharmaceutically acceptable salt, hydrate, or solvate thereof:
41. The compound for use, or the method, according to any one of claims 1 to 38, wherein the MCIM compound is a compound of the following formula, or a pharmaceutically acceptable salt, hydrate, or solvate thereof:
42. The compound for use, or the method, according to any one of claims 1 to 38, wherein the MCIM compound is a compound selected from compounds of the following formula, or a pharmaceutically acceptable salt, hydrate, or solvate thereof:
43. The compound for use, or the method, according to any one of claims 1 to 38, wherein the MCIM compound is a compound of the following formula, or a pharmaceutically acceptable salt, hydrate, or solvate thereof:
44. The compound for use, or the method, according to any one of claims 1 to 38, wherein administering the MCIM compound results in an increase in the subject’s grip strength and / or grip power compared to the subject’s grip strength and / or grip power prior to administration with the MCIM compound.
45. The compound for use, or the method, according to claim 44, wherein grip strength and / or grip power is increased compared to the subject’s grip strength and / or grip power prior to administration of the MCIM compound by 4 weeks, by 5 weeks, by 6 weeks, by 7 weeks, by 8 weeks, by 9 weeks, by 10 weeks, by 11 weeks, by 12 weeks, by 13 weeks, by 14 weeks, by 15 weeks, by 16 weeks, by 17 weeks, by 18 weeks, by 19 weeks, by 20 weeks, by 21 weeks, by 22 weeks, by 23 weeks, by 24 weeks, by 25 weeks, by 26 weeks, by 27 weeks, by 28 weeks, by 29 weeks, by 30 weeks, by 31 weeks, by 32 weeks, by 33 weeks, by 34 weeks, by 35 weeks, by 36 weeks, by 37 weeks, by 38 weeks, by 39 weeks, by 40 weeks, by 41 weeks, by 42 weeks, by 43 weeks, by 44 weeks, by 45 weeks, by 46 weeks, by 47 weeks, by 48 weeks, by 49 weeks, by 50 weeks, by 51 weeks, or by 52 weeks after first administration of the MCIM compound.
46. The compound for use, or the method, according to claim 44 or 45, wherein grip strength and / or grip power is increased by at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, or at least 25% compared to grip strength and / or grip power of the subject prior to the first administration of the MCIM compound.
47. The compound for use, or the method, according to any one of claims 1 to 38, wherein administering the MCIM compound prevents a decrease in grip strength and / or grip power of the subject compared to grip strength and / or grip power prior to the first administration of the MICIM compound.
48. The compound for use, or the method, according to claim 44 or 45, wherein grip strength is measured by dynamometer.
